[S02DA03, antipyrine, Antipyrine may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[G03XB02, ulipristal, The metabolism of Ulipristal can be increased when combined with Pregabalin.]
[B01AD01, streptokinase, The risk or severity of angioedema can be increased when Streptokinase is combined with Pregabalin.]
[J01GA01, streptomycin, Pregabalin may decrease the excretion rate of Streptomycin which could result in a higher serum level.]
[L04AA27, fingolimod, Pregabalin may increase the bradycardic activities of Fingolimod.]
[M03AB01, succinylcholine, The therapeutic efficacy of Succinylcholine can be increased when used in combination with Pregabalin.]
[A02BX02, sucralfate, Pregabalin may decrease the excretion rate of Sucralfate which could result in a higher serum level.]
[J01CG01, sulbactam, Pregabalin may decrease the excretion rate of Sulbactam which could result in a higher serum level.]
[J01EC02, sulfadiazine, The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Sulfadiazine.]
[J01EC01, sulfamethoxazole, The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Sulfamethoxazole.]
[S01AB02, sulfisoxazole, The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Sulfisoxazole.]
[M01AB02, sulindac, Sulindac may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[N05AL01, sulpiride, The therapeutic efficacy of Sulpiride can be increased when used in combination with Pregabalin.]
[N03AX03, sulthiame, The therapeutic efficacy of Sulthiame can be increased when used in combination with Pregabalin.]
[A10BB04, glibornuride, The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Glibornuride.]
[A10BC01, glymidine, The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Glymidine.]
[M01AX04, apazone, Azapropazone may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[L01BB02, mercaptopurine, Pregabalin may increase the excretion rate of Mercaptopurine which could result in a lower serum level and potentially a reduction in efficacy.]
[L02BA01, tamoxifen, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Tamoxifen.]
[N05CD07, temazepam, The therapeutic efficacy of Temazepam can be increased when used in combination with Pregabalin.]
[R03CC03, terbutaline, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Terbutaline.]
[B01AE07, dabigatran etexilate, Pregabalin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.]
[G03BA03, testosterone, Pregabalin may decrease the excretion rate of Testosterone which could result in a higher serum level.]
[N07XX06, tetrabenazine, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Tetrabenazine.]
[S01HA03, tetracaine, The therapeutic efficacy of Tetracaine can be increased when used in combination with Pregabalin.]
[S03AA02, tetracycline, Pregabalin may decrease the excretion rate of Tetracycline which could result in a higher serum level.]
[J01DI02, ceftaroline fosamil, Ceftaroline fosamil may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[N05AE05, lurasidone, The therapeutic efficacy of Lurasidone can be increased when used in combination with Pregabalin.]
[A04AD10, dronabinol, The therapeutic efficacy of Dronabinol can be increased when used in combination with Pregabalin.]
[N04BC07, apomorphine, The therapeutic efficacy of Apomorphine can be increased when used in combination with Pregabalin.]
[L04AX02, thalidomide, Pregabalin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R03DA07, theobromine, Pregabalin may increase the excretion rate of Theobromine which could result in a lower serum level and potentially a reduction in efficacy.]
[R03DA04, theophylline, Pregabalin may increase the excretion rate of Theophylline which could result in a lower serum level and potentially a reduction in efficacy.]
[P02CA02, thiabendazole, Pregabalin may decrease the excretion rate of Thiabendazole which could result in a higher serum level.]
[L01XX41, eribulin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Eribulin.]
[R06AD03, thiethylperazine, The therapeutic efficacy of Thiethylperazine can be increased when used in combination with Pregabalin.]
[N05CA19, thiopental, The therapeutic efficacy of Thiopental can be increased when used in combination with Pregabalin.]
[N05AB08, thioproperazine, The therapeutic efficacy of Thioproperazine can be increased when used in combination with Pregabalin.]
[N05AC02, thioridazine, The therapeutic efficacy of Thioridazine can be increased when used in combination with Pregabalin.]
[N05AF04, thiothixene, The therapeutic efficacy of Thiothixene can be increased when used in combination with Pregabalin.]
[G04BE06, moxisylyte, Pregabalin may decrease the excretion rate of Moxisylyte which could result in a higher serum level.]
[N05AL03, tiapride, The therapeutic efficacy of Tiapride can be increased when used in combination with Pregabalin.]
[B01AC05, ticlopidine, Ticlopidine may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[N02AX01, tilidine, The therapeutic efficacy of Tilidine can be increased when used in combination with Pregabalin.]
[S01ED01, timolol, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Timolol.]
[P01AB02, tinidazole, Pregabalin may decrease the excretion rate of Tinidazole which could result in a higher serum level.]
[S01AA12, tobramycin, Pregabalin may decrease the excretion rate of Tobramycin which could result in a higher serum level.]
[A10BB05, tolazamide, The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Tolazamide.]
[V04CA01, tolbutamide, The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Tolbutamide.]
[M02AA21, tolmetin, Tolmetin may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[M03BX04, tolperisone, The therapeutic efficacy of Tolperisone can be increased when used in combination with Pregabalin.]
[N02AX02, tramadol, The therapeutic efficacy of Tramadol can be increased when used in combination with Pregabalin.]
[N06AF04, tranylcypromine, The therapeutic efficacy of Tranylcypromine can be increased when used in combination with Pregabalin.]
[N06AX05, trazodone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Pregabalin.]
[C03DB02, triamterene, Triamterene may increase the excretion rate of Pregabalin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CD05, triazolam, The therapeutic efficacy of Triazolam can be increased when used in combination with Pregabalin.]
[C03AA06, trichlormethiazide, Trichlormethiazide may increase the excretion rate of Pregabalin which could result in a lower serum level and potentially a reduction in efficacy.]
[A03AB12, mepenzolate, Pregabalin may increase the central nervous system depressant (CNS depressant) activities of Mepenzolate.]
[A16AX12, trientine, Pregabalin may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.]
[N05AB06, trifluoperazine, The therapeutic efficacy of Trifluoperazine can be increased when used in combination with Pregabalin.]
[S01AD02, trifluridine, Pregabalin may decrease the excretion rate of Trifluridine which could result in a higher serum level.]
[N05AD02, trifluperidol, The therapeutic efficacy of Trifluperidol can be increased when used in combination with Pregabalin.]
[N05AA05, triflupromazine, The therapeutic efficacy of Triflupromazine can be increased when used in combination with Pregabalin.]
[N04AA01, trihexyphenidyl, Pregabalin may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.]
[A03AA05, trimebutine, Pregabalin may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[R06AD01, trimeprazine, The therapeutic efficacy of Alimemazine can be increased when used in combination with Pregabalin.]
[N03AC02, trimethadione, The therapeutic efficacy of Trimethadione can be increased when used in combination with Pregabalin.]
[J01EA01, trimethoprim, Pregabalin may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[N06AA06, trimipramine, The therapeutic efficacy of Trimipramine can be increased when used in combination with Pregabalin.]
[R06AX07, triprolidine, The therapeutic efficacy of Triprolidine can be increased when used in combination with Pregabalin.]
[A03BB01, butylscopolamine, Pregabalin may increase the central nervous system depressant (CNS depressant) activities of Butylscopolamine.]
[N06AX24, vilazodone, The therapeutic efficacy of Vilazodone can be increased when used in combination with Pregabalin.]
[N06AX02, tryptophan, The therapeutic efficacy of Tryptophan can be increased when used in combination with Pregabalin.]
[C09CA09, azilsartan medoxomil, The risk or severity of angioedema can be increased when Pregabalin is combined with Azilsartan medoxomil.]
[M03AA02, tubocurarine, The therapeutic efficacy of Tubocurarine can be increased when used in combination with Pregabalin.]
[R03DX07, roflumilast, Pregabalin may decrease the excretion rate of Roflumilast which could result in a higher serum level.]
[L01FX04, ipilimumab, Pregabalin may decrease the excretion rate of Ipilimumab which could result in a higher serum level.]
[L01EX04, vandetanib, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Vandetanib.]
[R02AA14, oxyquinoline, Pregabalin may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.]
[A10BH05, linagliptin, The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Linagliptin.]
[J05AG05, rilpivirine, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Rilpivirine.]
[B01AD04, urokinase, The risk or severity of angioedema can be increased when Urokinase is combined with Pregabalin.]
[S01AA28, vancomycin, Pregabalin may decrease the excretion rate of Vancomycin which could result in a higher serum level.]
[N03AX21, ezogabine, The therapeutic efficacy of Ezogabine can be increased when used in combination with Pregabalin.]
[B01AF01, rivaroxaban, Pregabalin may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.]
[R03AC18, indacaterol, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Indacaterol.]
[C08DA01, verapamil, Pregabalin may increase the bradycardic activities of Verapamil.]
[N06AX09, viloxazine, The therapeutic efficacy of Viloxazine can be increased when used in combination with Pregabalin.]
[B01AA03, warfarin, Pregabalin may decrease the excretion rate of Warfarin which could result in a higher serum level.]
[C03BA10, xipamide, Xipamide may increase the excretion rate of Pregabalin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AF05, zuclopenthixol, The therapeutic efficacy of Zuclopenthixol can be increased when used in combination with Pregabalin.]
[N03AX14, levetiracetam, The therapeutic efficacy of Levetiracetam can be increased when used in combination with Pregabalin.]
[L01EC01, vemurafenib, The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Pregabalin.]
[M05BA03, pamidronic acid, Pamidronic acid may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[M05BA05, tiludronic acid, Pregabalin may decrease the excretion rate of Tiludronic acid which could result in a higher serum level.]
[B06AC02, icatibant, The risk or severity of angioedema can be increased when Pregabalin is combined with Icatibant.]
[L01ED01, crizotinib, Crizotinib may increase the bradycardic activities of Pregabalin.]
[A02BC04, rabeprazole, Pregabalin may decrease the excretion rate of Rabeprazole which could result in a higher serum level.]
[M05BA06, ibandronic acid, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Ibandronate.]
[J01MA13, trovafloxacin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Trovafloxacin.]
[N05AE04, ziprasidone, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Ziprasidone.]
[G03AC10, drospirenone, The metabolism of Drospirenone can be increased when combined with Pregabalin.]
[V03AC02, deferiprone, Pregabalin may decrease the excretion rate of Deferiprone which could result in a higher serum level.]
[N02BA01, aspirin, The risk or severity of angioedema can be increased when Pregabalin is combined with Acetylsalicylic acid.]
[L01EJ01, ruxolitinib, Ruxolitinib may increase the bradycardic activities of Pregabalin.]
[G04BD07, tolterodine, Pregabalin may increase the central nervous system depressant (CNS depressant) activities of Tolterodine.]
[J01DH04, doripenem, Pregabalin may decrease the excretion rate of Doripenem which could result in a higher serum level.]
[C07AB03, atenolol, Pregabalin may increase the bradycardic activities of Atenolol.]
[J02AC03, voriconazole, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Voriconazole.]
[M03AC04, atracurium, The therapeutic efficacy of Atracurium can be increased when used in combination with Pregabalin.]
[S01FA01, atropine, Pregabalin may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[M01CB03, auranofin, Pregabalin may decrease the excretion rate of Auranofin which could result in a higher serum level.]
[B03XA04, peginesatide, Pregabalin may decrease the excretion rate of Peginesatide which could result in a higher serum level.]
[L01BC07, azacitidine, Pregabalin may decrease the excretion rate of Azacitidine which could result in a higher serum level.]
[L04AX01, azathioprine, Pregabalin may decrease the excretion rate of Azathioprine which could result in a higher serum level.]
[L01BC05, gemcitabine, Pregabalin may decrease the excretion rate of Gemcitabine which could result in a higher serum level.]
[J01CA09, azlocillin, The therapeutic efficacy of Pregabalin can be decreased when used in combination with Azlocillin.]
[J01DF01, aztreonam, Pregabalin may decrease the excretion rate of Aztreonam which could result in a higher serum level.]
[R02AB04, bacitracin, Bacitracin may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[M03BX01, baclofen, The therapeutic efficacy of Baclofen can be increased when used in combination with Pregabalin.]
[A08AA11, lorcaserin, The therapeutic efficacy of Lorcaserin can be increased when used in combination with Pregabalin.]
[G04BD12, mirabegron, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Mirabegron.]
[L02BB04, enzalutamide, Pregabalin may decrease the excretion rate of Enzalutamide which could result in a higher serum level.]
[L01EX05, regorafenib, Pregabalin may increase the bradycardic activities of Regorafenib.]
[N05CA04, barbital, The therapeutic efficacy of Barbital can be increased when used in combination with Pregabalin.]
[D02BA02, octinoxate, Pregabalin may decrease the excretion rate of Octinoxate which could result in a higher serum level.]
[J05AE04, nelfinavir, The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Pregabalin.]
[S01GA07, brimonidine, Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Pregabalin.]
[N04BD02, rasagiline, The therapeutic efficacy of Rasagiline can be increased when used in combination with Pregabalin.]
[C08CA13, lercanidipine, Pregabalin may increase the bradycardic activities of Lercanidipine.]
[A03FA09, mosapride, The therapeutic efficacy of Mosapride can be increased when used in combination with Pregabalin.]
[N06DA02, donepezil, The therapeutic efficacy of Donepezil can be increased when used in combination with Pregabalin.]
[N03AX22, perampanel, The therapeutic efficacy of Perampanel can be increased when used in combination with Pregabalin.]
[L04AA29, tofacitinib, Pregabalin may increase the bradycardic activities of Tofacitinib.]
[N02CC03, zolmitriptan, The therapeutic efficacy of Zolmitriptan can be increased when used in combination with Pregabalin.]
[R06AC06, thonzylamine, Pregabalin may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine.]
[G04BD10, darifenacin, Pregabalin may increase the central nervous system depressant (CNS depressant) activities of Darifenacin.]
[V09IX04, fluorodeoxyglucose F18, Pregabalin may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.]
[N01AA01, ethyl ether, The therapeutic efficacy of Diethyl ether can be increased when used in combination with Pregabalin.]
[H01CB05, pasireotide, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Pasireotide.]
[V08CA11, gadofosveset, Pregabalin may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.]
[A16AX08, teduglutide, Pregabalin may decrease the excretion rate of Teduglutide which could result in a higher serum level.]
[J04AK05, bedaquiline, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Bedaquiline.]
[C04AX11, bencyclane, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Bencyclane.]
[A10BH04, alogliptin, The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Alogliptin.]
[A16AX09, glycerol phenylbutyrate, Pregabalin may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level.]
[C03AA01, bendroflumethiazide, Bendroflumethiazide may increase the excretion rate of Pregabalin which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AX06, pomalidomide, The therapeutic efficacy of Pomalidomide can be increased when used in combination with Pregabalin.]
[N02BA10, benorilate, Benorilate may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[N05AD07, benperidol, The therapeutic efficacy of Benperidol can be increased when used in combination with Pregabalin.]
[A10BK02, canagliflozin, The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Canagliflozin.]
[J01MA15, gemifloxacin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Gemifloxacin.]
[S01AE07, moxifloxacin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Moxifloxacin.]
[A10AE05, insulin detemir, The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Insulin detemir.]
[R02AD01, benzocaine, The therapeutic efficacy of Benzocaine can be increased when used in combination with Pregabalin.]
[A10BX05, pramlintide, The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Pramlintide.]
[L03AA12, ancestim, Pregabalin may decrease the excretion rate of Ancestim which could result in a higher serum level.]
[M01AH01, celecoxib, Celecoxib may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[N02CC02, naratriptan, The therapeutic efficacy of Naratriptan can be increased when used in combination with Pregabalin.]
[N04AC01, benztropine, Pregabalin may increase the central nervous system depressant (CNS depressant) activities of Benzatropine.]
[L01EC02, dabrafenib, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Dabrafenib.]
[R02AX03, benzydamine, Benzydamine may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[L01EE01, trametinib, Pregabalin may decrease the excretion rate of Trametinib which could result in a higher serum level.]
[P03AX06, benzyl alcohol, The therapeutic efficacy of Benzyl alcohol can be increased when used in combination with Pregabalin.]
[V09AX05, florbetapir F-18, Pregabalin may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.]
[N06AX28, levomilnacipran, The therapeutic efficacy of Levomilnacipran can be increased when used in combination with Pregabalin.]
[C08EA02, bepridil, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Bepridil.]
[A10BJ03, lixisenatide, The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Lixisenatide.]
[C02KX04, macitentan, Pregabalin may decrease the excretion rate of Macitentan which could result in a higher serum level.]
[N06AX26, vortioxetine, The therapeutic efficacy of Vortioxetine can be increased when used in combination with Pregabalin.]
[G03AC08, etonogestrel, The metabolism of Etonogestrel can be increased when combined with Pregabalin.]
[N03AF04, eslicarbazepine, The therapeutic efficacy of Eslicarbazepine can be increased when used in combination with Pregabalin.]
[J05AP08, sofosbuvir, Pregabalin may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.]
[N03AG04, vigabatrin, The therapeutic efficacy of Vigabatrin can be increased when used in combination with Pregabalin.]
[A10BK01, dapagliflozin, The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Dapagliflozin.]
[C01CA27, droxidopa, Pregabalin may decrease the excretion rate of Droxidopa which could result in a higher serum level.]
[C07AB04, acebutolol, Pregabalin may increase the bradycardic activities of Acebutolol.]
[N05CH03, tasimelteon, The therapeutic efficacy of Tasimelteon can be increased when used in combination with Pregabalin.]
[L04AA32, apremilast, Pregabalin may decrease the excretion rate of Apremilast which could result in a higher serum level.]
[L02BG02, formestane, Pregabalin may decrease the excretion rate of Formestane which could result in a higher serum level.]
[S01ED02, betaxolol, Betaxolol may increase the bradycardic activities of Pregabalin.]
[V03AB34, fomepizole, Pregabalin may decrease the excretion rate of Fomepizole which could result in a higher serum level.]
[A10BJ04, albiglutide, The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Albiglutide.]
[L01ED02, ceritinib, Pregabalin may increase the bradycardic activities of Ceritinib.]
[A03BA03, hyoscyamine, Pregabalin may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.]
[N01AX05, alfaxalone, The therapeutic efficacy of Alfaxalone can be increased when used in combination with Pregabalin.]
[A10BK03, empagliflozin, The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Empagliflozin.]
[R03AC19, olodaterol, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Olodaterol.]
[V08AA01, diatrizoic acid, Pregabalin may decrease the excretion rate of Diatrizoate which could result in a higher serum level.]
[D11AA01, glycopyrronium, Pregabalin may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.]
[V08AA04, iothalamic acid, Pregabalin may decrease the excretion rate of Diatrizoate which could result in a higher serum level.]
[N05CM19, suvorexant, Pregabalin may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.]
[A16AX10, eliglustat, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Eliglustat.]
[S01AA15, dihydrostreptomycin, Dihydrostreptomycin may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[N05AA04, acepromazine, The therapeutic efficacy of Acepromazine can be increased when used in combination with Pregabalin.]
[A10BJ05, dulaglutide, The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Dulaglutide.]
[A06AH03, naloxegol, The risk or severity of respiratory depression can be increased when Naloxegol is combined with Pregabalin.]
[N04AA02, biperiden, Pregabalin may increase the central nervous system depressant (CNS depressant) activities of Biperiden.]
[S03AA06, gentamicin, Pregabalin may decrease the excretion rate of Gentamicin which could result in a higher serum level.]
[B01AF03, edoxaban, Pregabalin may decrease the excretion rate of Edoxaban which could result in a higher serum level.]
[N06AX11, mirtazapine, The therapeutic efficacy of Mirtazapine can be increased when used in combination with Pregabalin.]
[L01EX08, lenvatinib, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Lenvatinib.]
[L01XH03, panobinostat, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Panobinostat.]
[N02BE01, acetaminophen, Pregabalin may decrease the excretion rate of Acetaminophen which could result in a higher serum level.]
[L01DC01, bleomycin, Pregabalin may decrease the excretion rate of Bleomycin which could result in a higher serum level.]
[A03AA09, difemerine, Pregabalin may increase the central nervous system depressant (CNS depressant) activities of Difemerine.]
[C01EB17, ivabradine, Pregabalin may increase the bradycardic activities of Ivabradine.]
[J05AF08, adefovir dipivoxil, Adefovir dipivoxil may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[A07DA06, eluxadoline, The risk or severity of respiratory depression can be increased when Eluxadoline is combined with Pregabalin.]
[N05AX16, brexpiprazole, The therapeutic efficacy of Brexpiprazole can be increased when used in combination with Pregabalin.]
[G02CX02, flibanserin, The therapeutic efficacy of Flibanserin can be increased when used in combination with Pregabalin.]
[N05AX15, cariprazine, The therapeutic efficacy of Cariprazine can be increased when used in combination with Pregabalin.]
[A10BF01, acarbose, The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Acarbose.]
[M02AA25, aceclofenac, Aceclofenac may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[M01AB11, acemetacin, Acemetacin may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[S01EC01, acetazolamide, The therapeutic efficacy of Acetazolamide can be increased when used in combination with Pregabalin.]
[A10AE06, insulin degludec, The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Insulin degludec.]
[N05AB07, acetophenazine, The therapeutic efficacy of Acetophenazine can be increased when used in combination with Pregabalin.]
[V03AB37, idarucizumab, Pregabalin may decrease the excretion rate of Idarucizumab which could result in a higher serum level.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Pregabalin.]
[L01XG03, ixazomib, Pregabalin may decrease the excretion rate of Ixazomib which could result in a higher serum level.]
[A10BB31, acetohexamide, The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Acetohexamide.]
[G04CA01, alfuzosin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Alfuzosin.]
[M04AB05, lesinurad, Pregabalin may decrease the excretion rate of Lesinurad which could result in a higher serum level.]
[N05CA05, aprobarbital, The therapeutic efficacy of Aprobarbital can be increased when used in combination with Pregabalin.]
[M01AE16, alminoprofen, Alminoprofen may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[N03AX23, brivaracetam, The therapeutic efficacy of Brivaracetam can be increased when used in combination with Pregabalin.]
[N05BA08, bromazepam, The therapeutic efficacy of Bromazepam can be increased when used in combination with Pregabalin.]
[N04BC01, bromocriptine, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Pregabalin.]
[A02AD05, aluminum magnesium silicate, Pregabalin may decrease the excretion rate of Almasilate which could result in a higher serum level.]
[A03AX08, alverine, The therapeutic efficacy of Alverine can be increased when used in combination with Pregabalin.]
[R06AB01, brompheniramine, The therapeutic efficacy of Dexbrompheniramine can be increased when used in combination with Pregabalin.]
[N06AA19, amineptin, The therapeutic efficacy of Amineptine can be increased when used in combination with Pregabalin.]
[C08CA01, amlodipine, Pregabalin may increase the bradycardic activities of Amlodipine.]
[N06BX11, aniracetam, The therapeutic efficacy of Aniracetam can be increased when used in combination with Pregabalin.]
[C03CA02, bumetanide, Bumetanide may increase the excretion rate of Pregabalin which could result in a lower serum level and potentially a reduction in efficacy.]
[N01BB01, bupivacaine, The therapeutic efficacy of Levobupivacaine can be increased when used in combination with Pregabalin.]
[C07AA19, bupranolol, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Bupranolol.]
[N07BC01, buprenorphine, Pregabalin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[L02AE01, buserelin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Buserelin.]
[N05BE01, buspirone, The therapeutic efficacy of Buspirone can be increased when used in combination with Pregabalin.]
[L01XX27, arsenic trioxide, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Arsenic trioxide.]
[N06DA03, rivastigmine, Pregabalin may increase the bradycardic activities of Rivastigmine.]
[P01BE02, artemether, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Artemether.]
[M02AA03, clofezone, Pregabalin may decrease the excretion rate of Rabeprazole which could result in a higher serum level.]
[N02AF01, butorphanol, The therapeutic efficacy of Butorphanol can be increased when used in combination with Pregabalin.]
[J01MA09, sparfloxacin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Sparfloxacin.]
[R06AX09, azatadine, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Azatadine.]
[S01GX07, azelastine, Pregabalin may increase the central nervous system depressant (CNS depressant) activities of Azelastine.]
[S01AA26, azithromycin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Azithromycin.]
[L01EF02, ribociclib, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Ribociclib.]
[A07EC04, balsalazide, Balsalazide may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[R03DA08, bamifylline, Pregabalin may increase the excretion rate of Bamifylline which could result in a lower serum level and potentially a reduction in efficacy.]
[A06AH05, naldemedine, Pregabalin may decrease the excretion rate of Naldemedine which could result in a higher serum level.]
[N07XX16, deutetrabenazine, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Deutetrabenazine.]
[J01MB04, pipemidic acid, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Pipemidic acid.]
[N03AX30, beclamide, The therapeutic efficacy of Beclamide can be increased when used in combination with Pregabalin.]
[N06BC01, caffeine, Pregabalin may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.]
[C09AA07, benazepril, The risk or severity of angioedema can be increased when Pregabalin is combined with Benazepril.]
[A10BX06, benfluorex, The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Benfluorex.]
[S01HA02, benoxinate, The therapeutic efficacy of Oxybuprocaine can be increased when used in combination with Pregabalin.]
[P01CA02, benznidazole, Pregabalin may decrease the excretion rate of Benznidazole which could result in a higher serum level.]
[J01XX08, linezolid, The therapeutic efficacy of Pregabalin can be decreased when used in combination with Linezolid.]
[J05AF06, abacavir, Pregabalin may decrease the excretion rate of Abacavir which could result in a higher serum level.]
[N07XX13, valbenazine, Pregabalin may decrease the excretion rate of Valbenazine which could result in a higher serum level.]
[N04BD03, safinamide, The therapeutic efficacy of Safinamide can be increased when used in combination with Pregabalin.]
[J01MA23, delafloxacin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Delafloxacin.]
[L01BC06, capecitabine, Pregabalin may decrease the excretion rate of Capecitabine which could result in a higher serum level.]
[L01XH01, vorinostat, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Vorinostat.]
[C07AB07, bisoprolol, Pregabalin may increase the bradycardic activities of Bisoprolol.]
[J05AG03, efavirenz, The therapeutic efficacy of Efavirenz can be increased when used in combination with Pregabalin.]
[J01DC10, cefprozil, Cefprozil may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[C07AA17, bopindolol, Pregabalin may increase the bradycardic activities of Bopindolol.]
[N04AA11, bornaprine, Pregabalin may increase the central nervous system depressant (CNS depressant) activities of Bornaprine.]
[N05AD06, bromperidol, The therapeutic efficacy of Bromperidol can be increased when used in combination with Pregabalin.]
[N05CD09, brotizolam, The therapeutic efficacy of Brotizolam can be increased when used in combination with Pregabalin.]
[C03DA03, canrenone, Canrenone may increase the excretion rate of Pregabalin which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BA02, budesonide, Pregabalin may decrease the excretion rate of Budesonide which could result in a higher serum level.]
[M01AB07, bumadizone, Bumadizone may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[N05CA03, butobarbital, The therapeutic efficacy of Butobarbital can be increased when used in combination with Pregabalin.]
[N06AA15, butriptyline, The therapeutic efficacy of Butriptyline can be increased when used in combination with Pregabalin.]
[C01AA02, acetyldigoxins, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Acetyldigoxin.]
[A10BJ06, semaglutide, The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Semaglutide.]
[N01BX04, capsaicin, The risk or severity of methemoglobinemia can be increased when Pregabalin is combined with Capsaicin.]
[A10BK04, ertugliflozin, The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Ertugliflozin.]
[N05CA08, butylvinal, The therapeutic efficacy of Vinylbital can be increased when used in combination with Pregabalin.]
[R06AX18, acrivastine, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Acrivastine.]
[C09AA01, captopril, The risk or severity of angioedema can be increased when Pregabalin is combined with Captopril.]
[V04CD06, macimorelin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Macimorelin.]
[L02BB05, apalutamide, Pregabalin may decrease the excretion rate of Apalutamide which could result in a higher serum level.]
[A03AA03, camylofine, Pregabalin may increase the central nervous system depressant (CNS depressant) activities of Camylofin.]
[R06AA08, carbinoxamine, The therapeutic efficacy of Carbinoxamine can be increased when used in combination with Pregabalin.]
[C07AG02, carvedilol, Pregabalin may increase the bradycardic activities of Carvedilol.]
[N03AX24, cannabidiol, The therapeutic efficacy of Cannabidiol can be increased when used in combination with Pregabalin.]
[L04AA37, baricitinib, Pregabalin may decrease the excretion rate of Baricitinib which could result in a higher serum level.]
[J01DE01, cefepime, Cefepime may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[J01DD10, cefetamet, Cefetamet may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[J01DD09, cefodizime, Cefodizime may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[J01DC11, ceforanide, Ceforanide may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[J01DD13, cefpodoxime, Cefpodoxime may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[L01EC03, encorafenib, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Encorafenib.]
[J01DD14, ceftibuten, Ceftibuten may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[J01GB14, plazomicin, Pregabalin may decrease the excretion rate of Plazomicin which could result in a higher serum level.]
[C07AB08, celiprolol, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Celiprolol.]
[L01XX62, ivosidenib, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Ivosidenib.]
[A16AX14, migalastat, Pregabalin may decrease the excretion rate of Migalastat which could result in a higher serum level.]
[N03AX17, stiripentol, The therapeutic efficacy of Stiripentol can be increased when used in combination with Pregabalin.]
[S01GX12, cetirizine, The therapeutic efficacy of Cetirizine can be increased when used in combination with Pregabalin.]
[N05CM04, carbromal, The therapeutic efficacy of Carbromal can be increased when used in combination with Pregabalin.]
[A10BB06, carbutamide, The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Carbutamide.]
[N01BA04, chloroprocaine, The therapeutic efficacy of Chloroprocaine can be increased when used in combination with Pregabalin.]
[D08AE05, chloroxylenol, Pregabalin may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.]
[R06AA06, chlorphenoxamine, Pregabalin may increase the central nervous system depressant (CNS depressant) activities of Chlorphenoxamine.]
[M01AC05, lornoxicam, Lornoxicam may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[R03DA02, oxtriphylline, Pregabalin may increase the excretion rate of Oxtriphylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N07XX15, inotersen, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Inotersen.]
[M03BA02, carisoprodol, The therapeutic efficacy of Carisoprodol can be increased when used in combination with Pregabalin.]
[R03BB08, revefenacin, Pregabalin may increase the central nervous system depressant (CNS depressant) activities of Revefenacin.]
[L01AD01, carmustine, Pregabalin may decrease the excretion rate of Carmustine which could result in a higher serum level.]
[L01EX13, gilteritinib, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Gilteritinib.]
[L01XJ03, glasdegib, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Glasdegib.]
[N07XX05, amifampridine, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Amifampridine.]
[A06AX05, prucalopride, Pregabalin may decrease the excretion rate of Prucalopride which could result in a higher serum level.]
[C01BG07, cifenline, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Cibenzoline.]
[C09AA08, cilazapril, The risk or severity of angioedema can be increased when Pregabalin is combined with Cilazapril.]
[B01AC23, cilostazol, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Cilostazol.]
[A03FA08, cinitapride, The therapeutic efficacy of Cinitapride can be increased when used in combination with Pregabalin.]
[P02BX04, triclabendazole, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Triclabendazole.]
[N06AX27, esketamine, The therapeutic efficacy of Esketamine can be increased when used in combination with Pregabalin.]
[J01FA09, clarithromycin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Clarithromycin.]
[N06BA14, solriamfetol, The therapeutic efficacy of Solriamfetol can be increased when used in combination with Pregabalin.]
[N06AX29, brexanolone, The therapeutic efficacy of Brexanolone can be increased when used in combination with Pregabalin.]
[N05BA09, clobazam, The therapeutic efficacy of Clobazam can be increased when used in combination with Pregabalin.]
[N05BA22, cloxazolam, The therapeutic efficacy of Cloxazolam can be increased when used in combination with Pregabalin.]
[C01EB09, ubidecarenone, The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Ubidecarenone.]
[J01DC04, cefaclor, Cefaclor may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[J01DB05, cefadroxil, Cefadroxil may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[J01DC03, cefamandole, Cefamandole may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[J01DB07, cefatrizine, Cefatrizine may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[J01DB04, cefazolin, Cefazolin may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[J01DC09, cefmetazole, Cefmetazole may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[J01DC06, cefonicid, Cefonicid may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[J01DD12, cefoperazone, Cefoperazone may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[J01DD01, cefotaxime, The therapeutic efficacy of Pregabalin can be decreased when used in combination with Cefotaxime.]
[J01DC05, cefotetan, Cefotetan may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[N05AA06, cyamemazine, The therapeutic efficacy of Cyamemazine can be increased when used in combination with Pregabalin.]
[J01DC07, cefotiam, Cefotiam may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[J01DC01, cefoxitin, Cefoxitin may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[J01DD03, cefsulodin, Cefsulodin may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[J01DD02, ceftazidime, Ceftazidime may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[C03BX03, cicletanine, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Cicletanine.]
[J01DD07, ceftizoxime, Ceftizoxime may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[J01DD04, ceftriaxone, Ceftriaxone may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[S01AA27, cefuroxime, Cefuroxime may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[M03BX08, cyclobenzaprine, The therapeutic efficacy of Cyclobenzaprine can be increased when used in combination with Pregabalin.]
[L01EX14, entrectinib, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Entrectinib.]
[N07XX11, pitolisant, Pregabalin may increase the QTc-prolonging activities of Pitolisant.]
[J01XX12, lefamulin, Lefamulin may increase the QTc-prolonging activities of Pregabalin.]
[C03AA09, cyclothiazide, Cyclothiazide may increase the excretion rate of Pregabalin which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BE04, yohimbine, The therapeutic efficacy of Yohimbine can be increased when used in combination with Pregabalin.]
[A10AE03, insulin, regular, pork, The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Insulin pork.]
[J01XX09, daptomycin, Daptomycin may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[J01DB01, cephalexin, Cephalexin may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[J01DB02, cephaloridine, Cefaloridine may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[J01DB03, cephalothin, The therapeutic efficacy of Pregabalin can be decreased when used in combination with Cefalotin.]
[J01DB08, cephapirin, Cefapirin may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[J01DB09, cephradine, Cefradine may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[G03DB05, demegestone, The metabolism of Demegestone can be increased when combined with Pregabalin.]
[N02CC08, lasmiditan, The therapeutic efficacy of Lasmiditan can be increased when used in combination with Pregabalin.]
[G03AC09, desogestrel, The metabolism of Desogestrel can be increased when combined with Pregabalin.]
[A16AX16, givosiran, Givosiran may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[M09AX08, golodirsen, Pregabalin may decrease the excretion rate of Golodirsen which could result in a higher serum level.]
[R06AB06, dexbrompheniramine, The therapeutic efficacy of Dexbrompheniramine can be increased when used in combination with Pregabalin.]
[R06AB02, dexchlorpheniramine, The therapeutic efficacy of Pregabalin can be decreased when used in combination with Dexchlorpheniramine.]
[S01XA12, dexpanthenol, Pregabalin may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.]
[N02AX03, dezocine, The therapeutic efficacy of Dezocine can be increased when used in combination with Pregabalin.]
[N05CM21, lemborexant, The therapeutic efficacy of Lemborexant can be increased when used in combination with Pregabalin.]
[N05AD10, lumateperone, The therapeutic efficacy of Lumateperone can be increased when used in combination with Pregabalin.]
[S01AE06, gatifloxacin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Gatifloxacin.]
[N02CC07, frovatriptan, The therapeutic efficacy of Frovatriptan can be increased when used in combination with Pregabalin.]
[N05CC04, dichloralphenazone, The therapeutic efficacy of Dichloralphenazone can be increased when used in combination with Pregabalin.]
[R02AA03, dichlorobenzyl alcohol, Pregabalin may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.]
[G03DB08, dienogest, The metabolism of Dienogest can be increased when combined with Pregabalin.]
[A07DA04, difenoxin, The therapeutic efficacy of Difenoxin can be increased when used in combination with Pregabalin.]
[N02AA08, dihydrocodeine, The therapeutic efficacy of Dihydrocodeine can be increased when used in combination with Pregabalin.]
[N02CC06, eletriptan, The therapeutic efficacy of Eletriptan can be increased when used in combination with Pregabalin.]
[M01AH02, rofecoxib, Rofecoxib may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[C08CA16, clevidipine, Pregabalin may increase the bradycardic activities of Clevidipine.]
[C01BD07, dronedarone, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Dronedarone.]
[N03AG02, dipropylacetamide, The therapeutic efficacy of Valpromide can be increased when used in combination with Pregabalin.]
[L01AA02, chlorambucil, The therapeutic efficacy of Pregabalin can be decreased when used in combination with Chlorambucil.]
[R06AE04, chlorcyclizine, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Chlorcyclizine.]
[N05BA02, chlordiazepoxide, The therapeutic efficacy of Chlordiazepoxide can be increased when used in combination with Pregabalin.]
[A03AA08, dihexyverine, Pregabalin may increase the central nervous system depressant (CNS depressant) activities of Dihexyverine.]
[G04BD09, trospium, Pregabalin may increase the central nervous system depressant (CNS depressant) activities of Trospium.]
[M01AC04, droxicam, Droxicam may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[V08CA05, mangafodipir, Pregabalin may decrease the excretion rate of Mangafodipir which could result in a higher serum level.]
[M02AA27, dexketoprofen, Dexketoprofen may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[N05CM02, chlormethiazole, The therapeutic efficacy of Clomethiazole can be increased when used in combination with Pregabalin.]
[M03BB02, chlormezanone, The therapeutic efficacy of Chlormezanone can be increased when used in combination with Pregabalin.]
[R02AD04, dyclonine, The therapeutic efficacy of Dyclonine can be increased when used in combination with Pregabalin.]
[R06AX22, ebastine, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Ebastine.]
[J05AX29, fostemsavir, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Fostemsavir.]
[N05CD14, remimazolam, The therapeutic efficacy of Remimazolam can be increased when used in combination with Pregabalin.]
[N07XX04, sodium oxybate, Pregabalin may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.]
[N02AX07, oliceridine, The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Pregabalin is combined with Oliceridine.]
[P01BA01, chloroquine, The therapeutic efficacy of Pregabalin can be decreased when used in combination with Chloroquine.]
[C03AA04, chlorothiazide, Chlorothiazide may increase the excretion rate of Pregabalin which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AB04, chlorpheniramine, The therapeutic efficacy of Chlorpheniramine can be increased when used in combination with Pregabalin.]
[N05AA01, chlorpromazine, The therapeutic efficacy of Chlorpromazine can be increased when used in combination with Pregabalin.]
[A10BB02, chlorpropamide, The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Chlorpropamide.]
[N05AF03, chlorprothixene, The therapeutic efficacy of Chlorprothixene can be increased when used in combination with Pregabalin.]
[C03BA04, chlorthalidone, Chlorthalidone may increase the excretion rate of Pregabalin which could result in a lower serum level and potentially a reduction in efficacy.]
[M03BB03, chlorzoxazone, The therapeutic efficacy of Chlorzoxazone can be increased when used in combination with Pregabalin.]
[N05BX03, etifoxine, The therapeutic efficacy of Etifoxine can be increased when used in combination with Pregabalin.]
[N02BA07, ethenzamide, Ethenzamide may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[N02BA03, choline salicylate, Pregabalin may decrease the excretion rate of Choline salicylate which could result in a higher serum level.]
[N06BX18, vinpocetine, The therapeutic efficacy of Vinpocetine can be increased when used in combination with Pregabalin.]
[N05BA18, ethyl loflazepate, The therapeutic efficacy of Ethyl loflazepate can be increased when used in combination with Pregabalin.]
[G03DC06, ethynodiol, The metabolism of Etynodiol can be increased when combined with Pregabalin.]
[M01AB08, etodolac, Etodolac may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[M02AA06, etofenamate, Etofenamate may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[B06AC06, berotralstat, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Berotralstat.]
[L02BX04, relugolix, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Relugolix.]
[M01AX25, chondroitin sulfates, Pregabalin may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.]
[M03BA05, febarbamate, The therapeutic efficacy of Febarbamate can be increased when used in combination with Pregabalin.]
[N03AX10, felbamate, The therapeutic efficacy of Felbamate can be increased when used in combination with Pregabalin.]
[M01AE05, fenbufen, Fenbufen may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[N06BA10, fenethylline, Pregabalin may increase the excretion rate of Fenethylline which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA19, fenoldopam, Pregabalin may decrease the excretion rate of Fenoldopam which could result in a higher serum level.]
[J01DD15, cefdinir, Pregabalin may decrease the excretion rate of Cefdinir which could result in a higher serum level.]
[J01MB07, flumequine, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Flumequine.]
[S02BA08, fluocinolone acetonide, Pregabalin may decrease the excretion rate of Fluocinolone acetonide which could result in a higher serum level.]
[N02BG07, flupirtine, Pregabalin may decrease the excretion rate of Flupirtine which could result in a higher serum level.]
[R03CC15, formoterol, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Formoterol.]
[A10AF01, insulin, regular, human, The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Insulin human.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Pregabalin.]
[N01AB05, trichloroethylene, The therapeutic efficacy of Trichloroethylene can be increased when used in combination with Pregabalin.]
[A02BA01, cimetidine, Pregabalin may decrease the excretion rate of Cimetidine which could result in a higher serum level.]
[N02BF01, gabapentin, The therapeutic efficacy of Gabapentin can be increased when used in combination with Pregabalin.]
[V08CA04, gadoteridol, Pregabalin may decrease the excretion rate of Gadoteridol which could result in a higher serum level.]
[N07CA02, cinnarizine, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Cinnarizine.]
[J01MB06, cinoxacin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Cinoxacin.]
[S03AA07, ciprofloxacin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Ciprofloxacin.]
[L01XA01, cisplatin, Pregabalin may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N06AB04, citalopram, The therapeutic efficacy of Citalopram can be increased when used in combination with Pregabalin.]
[C03DA05, finerenone, Finerenone may increase the excretion rate of Pregabalin which could result in a lower serum level and potentially a reduction in efficacy.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Pregabalin is combined with Fexinidazole.]
[L01EB10, mobocertinib, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Mobocertinib.]
[R06AA04, clemastine, The therapeutic efficacy of Clemastine can be increased when used in combination with Pregabalin.]
[M01AG01, mefenamic acid, Mefenamic acid may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[A10BB12, glimepiride, The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Glimepiride.]
[A10BB08, gliquidone, The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Gliquidone.]
[N06AX25, St. John's wort extract, The therapeutic efficacy of St. John's Wort can be increased when used in combination with Pregabalin.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Pregabalin.]
[J04BA01, clofazimine, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Clofazimine.]
[B01AD11, tenecteplase, The risk or severity of angioedema can be increased when Tenecteplase is combined with Pregabalin.]
[N01BB10, levobupivacaine, The therapeutic efficacy of Levobupivacaine can be increased when used in combination with Pregabalin.]
[L01EJ03, pacritinib, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Pacritinib.]
[N06AA04, clomipramine, The therapeutic efficacy of Clomipramine can be increased when used in combination with Pregabalin.]
[N03AE01, clonazepam, The therapeutic efficacy of Clonazepam can be increased when used in combination with Pregabalin.]
[S01EA04, clonidine, The risk or severity of sedation can be increased when Clonidine is combined with Pregabalin.]
[J05AH02, oseltamivir, Oseltamivir may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[A10BX16, tirzepatide, The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Tirzepatide.]
[C03BA03, clopamide, Clopamide may increase the excretion rate of Pregabalin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AH06, clothiapine, The therapeutic efficacy of Clothiapine can be increased when used in combination with Pregabalin.]
[N05BA21, clotiazepam, The therapeutic efficacy of Clotiazepam can be increased when used in combination with Pregabalin.]
[A04AA01, ondansetron, The therapeutic efficacy of Ondansetron can be increased when used in combination with Pregabalin.]
[A04AA02, granisetron, The therapeutic efficacy of Granisetron can be increased when used in combination with Pregabalin.]
[N05AH02, clozapine, The therapeutic efficacy of Clozapine can be increased when used in combination with Pregabalin.]
[A10BX01, guar gum, The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Guar gum.]
[A10BK06, sotagliflozin, The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Sotagliflozin.]
[J01GB12, arbekacin, Pregabalin may decrease the excretion rate of Arbekacin which could result in a higher serum level.]
[N05BA13, halazepam, The therapeutic efficacy of Halazepam can be increased when used in combination with Pregabalin.]
[S02DA02, cocaine, The risk or severity of methemoglobinemia can be increased when Pregabalin is combined with Cocaine.]
[C02KB01, metyrosine, Pregabalin may increase the sedative activities of Metyrosine.]
[M01AX13, proquazone, Proquazone may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[R05DA04, codeine, The therapeutic efficacy of Codeine can be increased when used in combination with Pregabalin.]
[M03AC05, hexafluorenium, The therapeutic efficacy of Hexafluronium can be increased when used in combination with Pregabalin.]
[M04AC01, colchicine, Pregabalin may decrease the excretion rate of Colchicine which could result in a higher serum level.]
[A03AB10, hexocyclium, Pregabalin may increase the central nervous system depressant (CNS depressant) activities of Hexocyclium.]
[A03BB06, homatropine methylbromide, Pregabalin may increase the central nervous system depressant (CNS depressant) activities of Homatropine methylbromide.]
[J01XB01, colistin, Pregabalin may decrease the excretion rate of Colistin which could result in a higher serum level.]
[J01DE02, cefpirome, Cefpirome may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[N01AB07, desflurane, The therapeutic efficacy of Desflurane can be increased when used in combination with Pregabalin.]
[A04AA03, tropisetron, The therapeutic efficacy of Tropisetron can be increased when used in combination with Pregabalin.]
[C04AX28, ifenprodil, The therapeutic efficacy of Ifenprodil can be increased when used in combination with Pregabalin.]
[A10BX03, nateglinide, The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Nateglinide.]
[N02BA16, imidazole-2-hydroxybenzoate, Imidazole salicylate may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[H01AC03, mecasermin, The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Mecasermin.]
[A10AE04, insulin glargine, The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Insulin glargine.]
[J01FA15, telithromycin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Telithromycin.]
[B01AC10, indobufen, Indobufen may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[R06AX27, desloratadine, The therapeutic efficacy of Desloratadine can be increased when used in combination with Pregabalin.]
[J05AB14, valganciclovir, The therapeutic efficacy of Pregabalin can be decreased when used in combination with Valganciclovir.]
[C05BB03, invert sugar, Pregabalin may decrease the excretion rate of Invert sugar which could result in a higher serum level.]
[V08AB09, iodixanol, Pregabalin may decrease the excretion rate of Iodixanol which could result in a higher serum level.]
[V08AB05, iopromide, Pregabalin may decrease the excretion rate of Iopromide which could result in a higher serum level.]
[V08AB07, ioversol, Pregabalin may decrease the excretion rate of Ioversol which could result in a higher serum level.]
[V08AB12, ioxilan, Pregabalin may decrease the excretion rate of Ioxilan which could result in a higher serum level.]
[M01AH03, valdecoxib, Valdecoxib may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[H01AX01, pegvisomant, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Pregabalin.]
[N02CC05, almotriptan, The therapeutic efficacy of Almotriptan can be increased when used in combination with Pregabalin.]
[M01AH04, parecoxib, Parecoxib may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[J02AC02, itraconazole, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Itraconazole.]
[S01AD03, acyclovir, Acyclovir may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[S01GX06, emedastine, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Emedastine.]
[N05BA10, ketazolam, The therapeutic efficacy of Ketazolam can be increased when used in combination with Pregabalin.]
[M01AA06, kebuzone, Kebuzone may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[L01EA01, imatinib, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Imatinib.]
[J02AC04, posaconazole, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Posaconazole.]
[C08CA09, lacidipine, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Lacidipine.]
[S01GX02, levocabastine, The therapeutic efficacy of Levocabastine can be increased when used in combination with Pregabalin.]
[N07BC04, lofexidine, The therapeutic efficacy of Lofexidine can be increased when used in combination with Pregabalin.]
[S01AE04, lomefloxacin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Lomefloxacin.]
[M01AB09, lonazolac, Lonazolac may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[N05CD06, lormetazepam, The therapeutic efficacy of Lormetazepam can be increased when used in combination with Pregabalin.]
[H01AA02, cosyntropin, The risk or severity of liver damage can be increased when Tetracosactide is combined with Pregabalin.]
[M02AA31, loxoprofen, Loxoprofen may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[J01DC08, loracarbef, Loracarbef may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[C09AA03, lisinopril, The risk or severity of angioedema can be increased when Pregabalin is combined with Lisinopril.]
[A06AD01, magnesium carbonate, Pregabalin may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.]
[C08CA11, manidipine, Pregabalin may increase the bradycardic activities of Manidipine.]
[A03AA04, mebeverine, Pregabalin may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.]
[N06AX13, medifoxamine, The therapeutic efficacy of Medifoxamine can be increased when used in combination with Pregabalin.]
[C07AA14, mepindolol, Pregabalin may increase the bradycardic activities of Mepindolol.]
[R06AD07, mequitazine, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Mequitazine.]
[J01DH02, meropenem, Pregabalin may decrease the excretion rate of Meropenem which could result in a higher serum level.]
[C01EB10, adenosine, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Adenosine.]
[R06AD04, methdilazine, The therapeutic efficacy of Pregabalin can be decreased when used in combination with Methdilazine.]
[N04AA03, methixene, Pregabalin may increase the central nervous system depressant (CNS depressant) activities of Metixene.]
[C04AX01, cyclandelate, Pregabalin may increase the bradycardic activities of Cyclandelate.]
[R06AE03, cyclizine, The therapeutic efficacy of Cyclizine can be increased when used in combination with Pregabalin.]
[N05CA10, cyclobarbital, The therapeutic efficacy of Cyclobarbital can be increased when used in combination with Pregabalin.]
[C03DA04, eplerenone, Eplerenone may increase the excretion rate of Pregabalin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AD03, metylperon, The therapeutic efficacy of Melperone can be increased when used in combination with Pregabalin.]
[C03AA07, cyclopenthiazide, Cyclopenthiazide may increase the excretion rate of Pregabalin which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BF02, miglitol, The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Miglitol.]
[J05AF07, tenofovir disoproxil, Tenofovir disoproxil may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[N06AX07, minaprine, The therapeutic efficacy of Minaprine can be increased when used in combination with Pregabalin.]
[S01XA18, cyclosporine, The therapeutic efficacy of Pregabalin can be decreased when used in combination with Cyclosporine.]
[N06AG02, moclobemide, The therapeutic efficacy of Moclobemide can be increased when used in combination with Pregabalin.]
[R06AX02, cyproheptadine, The therapeutic efficacy of Cyproheptadine can be increased when used in combination with Pregabalin.]
[C09AA13, moexipril, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Moexipril.]
[M02AA02, mofebutazone, Mofebutazone may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[M01AX22, morniflumate, Morniflumate may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[C03XA02, conivaptan, Conivaptan may increase the excretion rate of Pregabalin which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BE09, vardenafil, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Vardenafil.]
[M01AH05, etoricoxib, Etoricoxib may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[L01AX04, dacarbazine, Pregabalin may decrease the excretion rate of Dacarbazine which could result in a higher serum level.]
[M03CA01, dantrolene, The therapeutic efficacy of Dantrolene can be increased when used in combination with Pregabalin.]
[N06BX04, deanol, The therapeutic efficacy of Deanol can be increased when used in combination with Pregabalin.]
[A04AD11, nabilone, The therapeutic efficacy of Nabilone can be increased when used in combination with Pregabalin.]
[M01AX01, nabumetone, Nabumetone may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[N07BB05, nalmefene, Pregabalin may decrease the excretion rate of Nalmefene which could result in a higher serum level.]
[N05BA16, nordazepam, The therapeutic efficacy of Nordazepam can be increased when used in combination with Pregabalin.]
[C07AB12, nebivolol, Pregabalin may increase the bradycardic activities of Nebivolol.]
[S01GX04, nedocromil, Pregabalin may decrease the excretion rate of Nedocromil which could result in a higher serum level.]
[N06AX06, nefazodone, The therapeutic efficacy of Nefazodone can be increased when used in combination with Pregabalin.]
[N05CM16, niaprazine, The therapeutic efficacy of Niaprazine can be increased when used in combination with Pregabalin.]
[C01DX16, nicorandil, Pregabalin may decrease the excretion rate of Nicorandil which could result in a higher serum level.]
[L02BB02, nilutamide, Pregabalin may decrease the excretion rate of Nilutamide which could result in a higher serum level.]
[N03AG06, tiagabine, The therapeutic efficacy of Tiagabine can be increased when used in combination with Pregabalin.]
[G03DB04, nomegestrol, The metabolism of Nomegestrol can be increased when combined with Pregabalin.]
[C01CA23, theodrenaline, Pregabalin may increase the excretion rate of Theodrenaline which could result in a lower serum level and potentially a reduction in efficacy.]
[M03AC11, cisatracurium, The therapeutic efficacy of Cisatracurium can be increased when used in combination with Pregabalin.]
[R05DA06, normethadone, The therapeutic efficacy of Normethadone can be increased when used in combination with Pregabalin.]
[B01AX05, fondaparinux, Pregabalin may decrease the excretion rate of Fondaparinux which could result in a higher serum level.]
[N06AB10, escitalopram, The therapeutic efficacy of Escitalopram can be increased when used in combination with Pregabalin.]
[G04BD08, solifenacin, Pregabalin may increase the central nervous system depressant (CNS depressant) activities of Solifenacin.]
[A07EC03, olsalazine, Olsalazine may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[N06AA01, desipramine, The therapeutic efficacy of Desipramine can be increased when used in combination with Pregabalin.]
[H01BA02, desmopressin, Desmopressin may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[V04CH02, indigo carmine, Pregabalin may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.]
[J01DH03, ertapenem, Pregabalin may decrease the excretion rate of Ertapenem which could result in a higher serum level.]
[L01XA03, oxaliplatin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Oxaliplatin.]
[M01AE12, oxaprozin, Oxaprozin may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[N03AF02, oxcarbazepine, The therapeutic efficacy of Oxcarbazepine can be increased when used in combination with Pregabalin.]
[N06BX07, oxiracetam, The therapeutic efficacy of Oxiracetam can be increased when used in combination with Pregabalin.]
[N04AA08, dexetimide, Pregabalin may increase the central nervous system depressant (CNS depressant) activities of Dexetimide.]
[G04BD04, oxybutynin, Pregabalin may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A03AA01, oxyphencyclimine, Pregabalin may increase the central nervous system depressant (CNS depressant) activities of Oxyphencyclimine.]
[N06BA02, dextroamphetamine, The therapeutic efficacy of Pregabalin can be decreased when used in combination with Amphetamine.]
[R05DA09, dextromethorphan, The therapeutic efficacy of Dextromethorphan can be increased when used in combination with Pregabalin.]
[N03AC01, paramethadione, The therapeutic efficacy of Paramethadione can be increased when used in combination with Pregabalin.]
[N02AC01, dextromoramide, The therapeutic efficacy of Dextromoramide can be increased when used in combination with Pregabalin.]
[N06AB05, paroxetine, The therapeutic efficacy of Paroxetine can be increased when used in combination with Pregabalin.]
[N07BC06, heroin, The therapeutic efficacy of Diamorphine can be increased when used in combination with Pregabalin.]
[C01DA05, pentaerythritol tetranitrate, Pregabalin may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.]
[C04AD01, pentifylline, Pregabalin may increase the excretion rate of Pentifylline which could result in a lower serum level and potentially a reduction in efficacy.]
[P03AC04, permethrin, Pregabalin may decrease the excretion rate of Permethrin which could result in a higher serum level.]
[N05BA01, diazepam, The therapeutic efficacy of Diazepam can be increased when used in combination with Pregabalin.]
[N03AX07, phenacemide, The therapeutic efficacy of Phenacemide can be increased when used in combination with Pregabalin.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Pregabalin is combined with Phenol.]
[N03AD02, phensuximide, The therapeutic efficacy of Phensuximide can be increased when used in combination with Pregabalin.]
[N06AA08, dibenzepin, The therapeutic efficacy of Dibenzepin can be increased when used in combination with Pregabalin.]
[S02DA04, dibucaine, The therapeutic efficacy of Cinchocaine can be increased when used in combination with Pregabalin.]
[R05DA08, pholcodine, Pregabalin may decrease the excretion rate of Pholcodine which could result in a higher serum level.]
[S01EC02, dichlorphenamide, Diclofenamide may increase the excretion rate of Pregabalin which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC03, diclofenac, The risk or severity of angioedema can be increased when Pregabalin is combined with Diclofenac.]
[J05AD01, foscarnet, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Foscarnet.]
[A03AA07, dicyclomine, Pregabalin may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.]
[J05AF02, didanosine, Pregabalin may decrease the excretion rate of Didanosine which could result in a higher serum level.]
[A03AX04, pinaverium, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Pinaverium.]
[A10BG03, pioglitazone, The risk or severity of weight gain and edema formation can be increased when Pregabalin is combined with Pioglitazone.]
[N05AD05, pipamperone, The therapeutic efficacy of Pipamperone can be increased when used in combination with Pregabalin.]
[A03AB14, pipenzolate, Pregabalin may increase the central nervous system depressant (CNS depressant) activities of Pipenzolate.]
[L01EB02, erlotinib, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Erlotinib.]
[C03CA03, piretanide, Piretanide may increase the excretion rate of Pregabalin which could result in a lower serum level and potentially a reduction in efficacy.]
[A08AA03, diethylpropion, The therapeutic efficacy of Diethylpropion can be increased when used in combination with Pregabalin.]
[L02AA01, diethylstilbestrol, The metabolism of Diethylstilbestrol can be increased when combined with Pregabalin.]
[C08CA03, isradipine, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Isradipine.]
[D07XC04, diflucortolone, Pregabalin may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[A03AB11, poldine, Pregabalin may increase the central nervous system depressant (CNS depressant) activities of Poldine.]
[N02BA11, diflunisal, Diflunisal may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[C01AA04, digitoxin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Digitoxin.]
[C01AA05, digoxin, Pregabalin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N02CA01, dihydroergotamine, The therapeutic efficacy of Dihydroergotamine can be increased when used in combination with Pregabalin.]
[N02AA03, hydromorphone, The therapeutic efficacy of Hydromorphone can be increased when used in combination with Pregabalin.]
[L04AX04, lenalidomide, Pregabalin may decrease the excretion rate of Lenalidomide which could result in a higher serum level.]
[J05AE08, atazanavir, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Atazanavir.]
[B01AC21, treprostinil, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Treprostinil.]
[H03BC01, potassium perchlorate, Pregabalin may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level.]
[V03AB04, pralidoxime, Pregabalin may decrease the excretion rate of Pralidoxime which could result in a higher serum level.]
[D04AB07, pramoxine, The therapeutic efficacy of Pramocaine can be increased when used in combination with Pregabalin.]
[C08DB01, diltiazem, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Diltiazem.]
[R06AA11, dimenhydrinate, The therapeutic efficacy of Dimenhydrinate can be increased when used in combination with Pregabalin.]
[V03AB09, dimercaprol, Pregabalin may decrease the excretion rate of Dimercaprol which could result in a higher serum level.]
[M03BX03, pridinol, The therapeutic efficacy of Pridinol can be increased when used in combination with Pregabalin.]
[R06AB03, dimethindene, Pregabalin may increase the central nervous system depressant (CNS depressant) activities of Dimetindene.]
[M02AX03, dimethyl sulfoxide, Pregabalin may decrease the excretion rate of Dimethyl sulfoxide which could result in a higher serum level.]
[N03AG05, progabide, The therapeutic efficacy of Progabide can be increased when used in combination with Pregabalin.]
[N06BC02, propentofylline, Pregabalin may increase the excretion rate of Propentofylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BB04, propyphenazone, Propyphenazone may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[M01AB14, proglumetacin, Proglumetacin may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Pregabalin is combined with Proparacaine.]
[R03DA03, proxyphylline, Pregabalin may increase the excretion rate of Proxyphylline which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AA02, diphenhydramine, The therapeutic efficacy of Diphenhydramine can be increased when used in combination with Pregabalin.]
[A07DA01, diphenoxylate, The therapeutic efficacy of Diphenoxylate can be increased when used in combination with Pregabalin.]
[N05CD10, quazepam, The therapeutic efficacy of Quazepam can be increased when used in combination with Pregabalin.]
[C09AA06, quinapril, The risk or severity of angioedema can be increased when Pregabalin is combined with Quinapril.]
[N06BA11, dexmethylphenidate, The therapeutic efficacy of Dexmethylphenidate can be increased when used in combination with Pregabalin.]
[N06AA23, quinupramine, The therapeutic efficacy of Quinupramine can be increased when used in combination with Pregabalin.]
[A03FA02, cisapride, The therapeutic efficacy of Cisapride can be increased when used in combination with Pregabalin.]
[C09AA05, ramipril, The risk or severity of angioedema can be increased when Ramipril is combined with Pregabalin.]
[S01XA23, sirolimus, The risk or severity of angioedema can be increased when Pregabalin is combined with Sirolimus.]
[N05AL04, remoxipride, The therapeutic efficacy of Remoxipride can be increased when used in combination with Pregabalin.]
[S01AX06, resorcinol, Pregabalin may decrease the excretion rate of Resorcinol which could result in a higher serum level.]
[C01BA03, disopyramide, Pregabalin may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[P03AA04, disulfiram, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Disulfiram.]
[N07XX02, riluzole, The therapeutic efficacy of Riluzole can be increased when used in combination with Pregabalin.]
[N05AX08, risperidone, The therapeutic efficacy of Risperidone can be increased when used in combination with Pregabalin.]
[R06AE09, levocetirizine, The therapeutic efficacy of Levocetirizine can be increased when used in combination with Pregabalin.]
[N01BB09, ropivacaine, The therapeutic efficacy of Ropivacaine can be increased when used in combination with Pregabalin.]
[J01MB01, rosoxacin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Rosoxacin.]
[L01EX01, sunitinib, The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Sunitinib.]
[C03XA01, tolvaptan, Tolvaptan may increase the excretion rate of Pregabalin which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XG01, bortezomib, The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Pregabalin.]
[G04BE08, tadalafil, Pregabalin may decrease the excretion rate of Tadalafil which could result in a higher serum level.]
[S01BC05, ketorolac, Ketorolac may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[C01EB18, ranolazine, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Ranolazine.]
[N02BA06, salsalate, Salsalate may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[R03AC12, salmeterol, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Salmeterol.]
[H05BA01, salmon calcitonin, Salmon calcitonin may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[C01CA07, dobutamine, Pregabalin may decrease the excretion rate of Dobutamine which could result in a higher serum level.]
[A03FA03, domperidone, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Domperidone.]
[C01CA04, dopamine, Pregabalin may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[N06AA16, dothiepin, The therapeutic efficacy of Dosulepin can be increased when used in combination with Pregabalin.]
[N06AA12, doxepin, The therapeutic efficacy of Doxepin can be increased when used in combination with Pregabalin.]
[J01AA02, doxycycline, Pregabalin may decrease the excretion rate of Doxycycline which could result in a higher serum level.]
[R06AA09, doxylamine, Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Pregabalin.]
[N06AB06, sertraline, The therapeutic efficacy of Sertraline can be increased when used in combination with Pregabalin.]
[N01AB08, sevoflurane, The therapeutic efficacy of Sevoflurane can be increased when used in combination with Pregabalin.]
[N05AD08, droperidol, The therapeutic efficacy of Droperidol can be increased when used in combination with Pregabalin.]
[A08AA10, sibutramine, The therapeutic efficacy of Sibutramine can be increased when used in combination with Pregabalin.]
[V03AG05, sodium phosphate, The therapeutic efficacy of Pregabalin can be decreased when used in combination with Sodium phosphate, monobasic.]
[A12CA02, sodium sulfate, Pregabalin may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.]
[C09AA11, spirapril, The risk or severity of angioedema can be increased when Pregabalin is combined with Spirapril.]
[R03DA01, dyphylline, Pregabalin may increase the excretion rate of Dyphylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AL02, sultopride, The therapeutic efficacy of Sultopride can be increased when used in combination with Pregabalin.]
[N02CC01, sumatriptan, The therapeutic efficacy of Sumatriptan can be increased when used in combination with Pregabalin.]
[V04CX07, edrophonium, Pregabalin may decrease the excretion rate of Edrophonium which could result in a higher serum level.]
[C07AB13, talinolol, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Talinolol.]
[J01MA05, temafloxacin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Temafloxacin.]
[L01AX03, temozolomide, Pregabalin may decrease the excretion rate of Temozolomide which could result in a higher serum level.]
[M01AC02, tenoxicam, Tenoxicam may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[G04BD05, terodiline, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Terodiline.]
[C07AA16, tertatolol, Pregabalin may increase the bradycardic activities of Tertatolol.]
[A08AB01, orlistat, Orlistat can cause a decrease in the absorption of Pregabalin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[M03BX07, tetrazepam, The therapeutic efficacy of Tetrazepam can be increased when used in combination with Pregabalin.]
[M03BX05, thiocolchicoside, The therapeutic efficacy of Thiocolchicoside can be increased when used in combination with Pregabalin.]
[N05AB05, thiopropazate, The therapeutic efficacy of Thiopropazate can be increased when used in combination with Pregabalin.]
[G04BD01, emepronium, The therapeutic efficacy of Emepronium can be increased when used in combination with Pregabalin.]
[N06AX14, tianeptine, The therapeutic efficacy of Tianeptine can be increased when used in combination with Pregabalin.]
[C09AA02, enalapril, The risk or severity of angioedema can be increased when Pregabalin is combined with Enalapril.]
[N05BA23, tofisopam, The therapeutic efficacy of Tofisopam can be increased when used in combination with Pregabalin.]
[M01AG02, tolfenamic acid, Pregabalin may increase the bradycardic activities of Tolfenamic acid.]
[N06AG03, toloxatone, The therapeutic efficacy of Toloxatone can be increased when used in combination with Pregabalin.]
[N06BA09, atomoxetine, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Atomoxetine.]
[L02BA02, toremifene, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Toremifene.]
[C03CA04, torsemide, Torasemide may increase the excretion rate of Pregabalin which could result in a lower serum level and potentially a reduction in efficacy.]
[C09AA10, trandolapril, The risk or severity of angioedema can be increased when Pregabalin is combined with Trandolapril.]
[N05CD11, triazulenone, The therapeutic efficacy of Loprazolam can be increased when used in combination with Pregabalin.]
[N05CC01, chloral hydrate, The therapeutic efficacy of Chloral hydrate can be increased when used in combination with Pregabalin.]
[N05CM07, triclofos, The therapeutic efficacy of Triclofos can be increased when used in combination with Pregabalin.]
[A03AB08, tridihexethyl, Pregabalin may increase the central nervous system depressant (CNS depressant) activities of Tridihexethyl.]
[R06AA10, trimethobenzamide, The therapeutic efficacy of Trimethobenzamide can be increased when used in combination with Pregabalin.]
[L02AE04, triptorelin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Triptorelin.]
[N04AA12, tropatepine, Pregabalin may increase the central nervous system depressant (CNS depressant) activities of Tropatepine.]
[N01AB04, enflurane, The therapeutic efficacy of Enflurane can be increased when used in combination with Pregabalin.]
[C02CA06, urapidil, The therapeutic efficacy of Urapidil can be increased when used in combination with Pregabalin.]
[J01MA04, enoxacin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Enoxacin.]
[N05AL06, veralipride, The therapeutic efficacy of Veralipride can be increased when used in combination with Pregabalin.]
[S01GX10, epinastine, The therapeutic efficacy of Epinastine can be increased when used in combination with Pregabalin.]
[N06AX16, venlafaxine, The therapeutic efficacy of Venlafaxine can be increased when used in combination with Pregabalin.]
[C08CA12, mepirodipine, Pregabalin may increase the bradycardic activities of Barnidipine.]
[C09AA15, zofenopril, The risk or severity of angioedema can be increased when Pregabalin is combined with Zofenopril.]
[N05CF02, zolpidem, Pregabalin may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.]
[M01AB04, zomepirac, Zomepirac may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[N03AX15, zonisamide, The therapeutic efficacy of Zonisamide can be increased when used in combination with Pregabalin.]
[A10AB06, insulin glulisine, human, The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Insulin glulisine.]
[N05CF01, zopiclone, The therapeutic efficacy of Zopiclone can be increased when used in combination with Pregabalin.]
[N05AX11, zotepine, The therapeutic efficacy of Zotepine can be increased when used in combination with Pregabalin.]
[B01AD03, anistreplase, The risk or severity of angioedema can be increased when Anistreplase is combined with Pregabalin.]
[L01XA02, carboplatin, Carboplatin may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[C02AC02, guanfacine, The therapeutic efficacy of Guanfacine can be increased when used in combination with Pregabalin.]
[C01BG01, moricizine, The therapeutic efficacy of Moricizine can be increased when used in combination with Pregabalin.]
[G02AB03, ergonovine, The therapeutic efficacy of Ergometrine can be increased when used in combination with Pregabalin.]
[C04AE01, ergoloid mesylates, USP, The therapeutic efficacy of Ergoloid mesylate can be increased when used in combination with Pregabalin.]
[N02CA02, ergotamine, The therapeutic efficacy of Ergotamine can be increased when used in combination with Pregabalin.]
[L03AX05, pidotimod, Pregabalin may decrease the excretion rate of Pidotimod which could result in a higher serum level.]
[S01AA17, erythromycin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Erythromycin.]
[N05CD04, estazolam, The therapeutic efficacy of Estazolam can be increased when used in combination with Pregabalin.]
[A02BC02, pantoprazole, Pantoprazole may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[G03CA03, estradiol, The metabolism of Estradiol can be increased when combined with Pregabalin.]
[G03CA57, estrogens, conjugated (USP), The risk or severity of angioedema can be increased when Pregabalin is combined with Conjugated estrogens.]
[J04AK02, ethambutol, Pregabalin may decrease the excretion rate of Ethambutol which could result in a higher serum level.]
[V08CA03, gadodiamide, Gadodiamide may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[N05CM08, ethchlorvynol, The therapeutic efficacy of Ethchlorvynol can be increased when used in combination with Pregabalin.]
[L02AA03, ethinyl estradiol, The metabolism of Ethinylestradiol can be increased when combined with Pregabalin.]
[C01BD05, ibutilide, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Ibutilide.]
[N04AA05, profenamine, Pregabalin may increase the central nervous system depressant (CNS depressant) activities of Profenamine.]
[N03AD01, ethosuximide, The therapeutic efficacy of Ethosuximide can be increased when used in combination with Pregabalin.]
[N03AB01, ethotoin, The therapeutic efficacy of Ethotoin can be increased when used in combination with Pregabalin.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Pregabalin is combined with Ethyl chloride.]
[M01AC06, meloxicam, The risk or severity of methemoglobinemia can be increased when Pregabalin is combined with Meloxicam.]
[S01XA06, ethylmorphine, The therapeutic efficacy of Ethylmorphine can be increased when used in combination with Pregabalin.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Pregabalin is combined with Etidocaine.]
[N01AX07, etomidate, The therapeutic efficacy of Etomidate can be increased when used in combination with Pregabalin.]
[N05AE03, sertindole, The therapeutic efficacy of Sertindole can be increased when used in combination with Pregabalin.]
[C01BA05, ajmaline, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Ajmaline.]
[L04AD02, tacrolimus, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Tacrolimus.]
[J01MA08, fleroxacin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Fleroxacin.]
[R06AX11, astemizole, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Astemizole.]
[R06AX12, terfenadine, Pregabalin may increase the central nervous system depressant (CNS depressant) activities of Terfenadine.]
[P01AX07, trimetrexate, Pregabalin may decrease the excretion rate of Trimetrexate which could result in a higher serum level.]
[N06AX12, bupropion, The therapeutic efficacy of Bupropion can be increased when used in combination with Pregabalin.]
[N06AB08, fluvoxamine, The therapeutic efficacy of Fluvoxamine can be increased when used in combination with Pregabalin.]
[C01BC08, encainide, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Encainide.]
[L02AE02, leuprolide, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Leuprolide.]
[M01CB01, gold sodium thiomalate, Pregabalin may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.]
[B05AA05, dextran, Pregabalin may decrease the excretion rate of Dextran which could result in a higher serum level.]
[V03AF02, dexrazoxane, Pregabalin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.]
[A02BA03, famotidine, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Famotidine.]
[A16AA01, levocarnitine, Pregabalin may decrease the excretion rate of Levocarnitine which could result in a higher serum level.]
[C08CA02, felodipine, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Felodipine.]
[C08EA01, fendiline, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Fendiline.]
[N03AX26, fenfluramine, The therapeutic efficacy of Fenfluramine can be increased when used in combination with Pregabalin.]
[M01AE04, fenoprofen, Fenoprofen may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[N02AB03, fentanyl, The therapeutic efficacy of Fentanyl can be increased when used in combination with Pregabalin.]
[R03CC02, albuterol, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Salbutamol.]
[L01BB06, clofarabine, Pregabalin may decrease the excretion rate of Clofarabine which could result in a higher serum level.]
[N07AX03, cevimeline, Cevimeline may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[G04BD02, flavoxate, Pregabalin may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.]
[C01BC04, flecainide, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Flecainide.]
[N02BG04, floctafenine, Floctafenine may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[J02AC01, fluconazole, The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Pregabalin.]
[J02AX01, flucytosine, Pregabalin may decrease the excretion rate of Flucytosine which could result in a higher serum level.]
[V03AB25, flumazenil, Pregabalin may decrease the excretion rate of Flumazenil which could result in a higher serum level.]
[N07CA03, flunarizine, The therapeutic efficacy of Flunarizine can be increased when used in combination with Pregabalin.]
[N05CD03, flunitrazepam, The therapeutic efficacy of Flunitrazepam can be increased when used in combination with Pregabalin.]
[N06AA14, melitracen, The therapeutic efficacy of Melitracen can be increased when used in combination with Pregabalin.]
[V03AZ01, ethanol, Pregabalin may increase the central nervous system depressant (CNS depressant) activities of Ethanol.]
[L01BC09, floxuridine, Pregabalin may decrease the excretion rate of Floxuridine which could result in a higher serum level.]
[L01BC02, fluorouracil, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Fluorouracil.]
[N06AB03, fluoxetine, The therapeutic efficacy of Fluoxetine can be increased when used in combination with Pregabalin.]
[N05AF01, flupenthixol, The therapeutic efficacy of Flupentixol can be increased when used in combination with Pregabalin.]
[N05AB02, fluphenazine, The therapeutic efficacy of Fluphenazine can be increased when used in combination with Pregabalin.]
[N05CD01, flurazepam, The therapeutic efficacy of Flurazepam can be increased when used in combination with Pregabalin.]
[S01BC04, flurbiprofen, Flurbiprofen may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[N05AG01, fluspirilene, The therapeutic efficacy of Fluspirilene can be increased when used in combination with Pregabalin.]
[L02BB01, flutamide, Pregabalin may decrease the excretion rate of Flutamide which could result in a higher serum level.]
[V04CX02, folic acid, Folic acid may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[S02AA17, fosfomycin, Pregabalin may decrease the excretion rate of Fosfomycin which could result in a higher serum level.]
[S01AA07, framycetin, Framycetin may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[L01BC03, tegafur, Pregabalin may decrease the excretion rate of Tegafur which could result in a higher serum level.]
[M03AA01, alcuronium, The therapeutic efficacy of Alcuronium can be increased when used in combination with Pregabalin.]
[G01AX06, furazolidone, The therapeutic efficacy of Furazolidone can be increased when used in combination with Pregabalin.]
[C03CA01, furosemide, Furosemide may increase the excretion rate of Pregabalin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CF04, eszopiclone, The therapeutic efficacy of Eszopiclone can be increased when used in combination with Pregabalin.]
[N05AL05, amisulpride, The therapeutic efficacy of Amisulpride can be increased when used in combination with Pregabalin.]
[N06DA04, galantamine, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Galantamine.]
[M03AC02, gallamine, The therapeutic efficacy of Gallamine can be increased when used in combination with Pregabalin.]
[C08DA02, gallopamil, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Gallopamil.]
[S01AD09, ganciclovir, The therapeutic efficacy of Pregabalin can be decreased when used in combination with Ganciclovir.]
[N03AA04, barbexaclone, The therapeutic efficacy of Barbexaclone can be increased when used in combination with Pregabalin.]
[N06AX08, bifemelane, The therapeutic efficacy of Bifemelane can be increased when used in combination with Pregabalin.]
[C10AB04, gemfibrozil, Pregabalin may decrease the excretion rate of Gemfibrozil which could result in a higher serum level.]
[J01XA03, telavancin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Telavancin.]
[L02BX02, degarelix, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Degarelix.]
[L01EA02, dasatinib, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Dasatinib.]
[N04BC06, cabergoline, The therapeutic efficacy of Cabergoline can be increased when used in combination with Pregabalin.]
[C01CA21, cafedrine, Pregabalin may increase the excretion rate of Cafedrine which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BJ02, liraglutide, The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Liraglutide.]
[N03AD03, methsuximide, The therapeutic efficacy of Methsuximide can be increased when used in combination with Pregabalin.]
[G03XA02, gestrinone, The metabolism of Gestrinone can be increased when combined with Pregabalin.]
[N01AH02, alfentanil, The therapeutic efficacy of Alfentanil can be increased when used in combination with Pregabalin.]
[L01EH01, lapatinib, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Lapatinib.]
[A10BB01, glyburide, The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Glyburide.]
[A10BB09, gliclazide, The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Gliclazide.]
[A10BB07, glipizide, The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Glipizide.]
[N05CM18, dexmedetomidine, The therapeutic efficacy of Dexmedetomidine can be increased when used in combination with Pregabalin.]
[N05CE01, glutethimide, The therapeutic efficacy of Glutethimide can be increased when used in combination with Pregabalin.]
[C01BD04, dofetilide, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Dofetilide.]
[L01EX02, sorafenib, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Sorafenib.]
[C07AB09, esmolol, The risk or severity of QTc prolongation can be increased when Esmolol is combined with Pregabalin.]
[M01CB04, aurothioglucose, Pregabalin may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.]
[S01LA03, pegaptanib, Pregabalin may decrease the excretion rate of Pegaptanib which could result in a higher serum level.]
[C09AA09, fosinopril, The risk or severity of angioedema can be increased when Pregabalin is combined with Fosinopril.]
[S01EX01, guanethidine, Pregabalin may decrease the excretion rate of Guanethidine which could result in a higher serum level.]
[L02AE03, goserelin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Goserelin.]
[P01BX01, halofantrine, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Halofantrine.]
[N05AD01, haloperidol, The therapeutic efficacy of Haloperidol can be increased when used in combination with Pregabalin.]
[N01AB01, halothane, The therapeutic efficacy of Halothane can be increased when used in combination with Pregabalin.]
[L02AE05, histrelin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Histrelin.]
[N05AH04, quetiapine, The therapeutic efficacy of Quetiapine can be increased when used in combination with Pregabalin.]
[N06BX13, idebenone, Pregabalin may decrease the excretion rate of Idebenone which could result in a higher serum level.]
[A10AD05, insulin aspart, human, The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Insulin aspart.]
[N02CX03, iprazochrome, The therapeutic efficacy of Iprazochrome can be increased when used in combination with Pregabalin.]
[N05CA21, allobarbital, The therapeutic efficacy of Allobarbital can be increased when used in combination with Pregabalin.]
[M04AA01, allopurinol, Pregabalin may decrease the excretion rate of Allopurinol which could result in a higher serum level.]
[C09CA01, losartan, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Losartan.]
[G03DC01, allylestrenol, Pregabalin may decrease the excretion rate of Allylestrenol which could result in a higher serum level.]
[A07EC02, mesalamine, Mesalazine may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[C01CE02, milrinone, Pregabalin may decrease the excretion rate of Milrinone which could result in a higher serum level.]
[N05CA16, hexobarbital, The therapeutic efficacy of Hexobarbital can be increased when used in combination with Pregabalin.]
[C08CA10, nilvadipine, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Nilvadipine.]
[M02AA26, nimesulide, Pregabalin may increase the bradycardic activities of Nimesulide.]
[R06AE06, oxatomide, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Oxatomide.]
[C09AA04, perindopril, The risk or severity of angioedema can be increased when Pregabalin is combined with Perindopril.]
[C02DB02, hydralazine, Pregabalin may decrease the excretion rate of Hydralazine which could result in a higher serum level.]
[C03AA03, hydrochlorothiazide, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Hydrochlorothiazide.]
[R05DA03, hydrocodone, Pregabalin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.]
[C03AA02, hydroflumethiazide, Hydroflumethiazide may increase the excretion rate of Pregabalin which could result in a lower serum level and potentially a reduction in efficacy.]
[B05XA17, potassium acetate, Pregabalin may decrease the excretion rate of Potassium acetate which could result in a higher serum level.]
[A12BA02, potassium citrate, Potassium citrate may increase the excretion rate of Pregabalin which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB33, hydroxocobalamin, Hydroxocobalamin may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[G04BD06, propiverine, Pregabalin may increase the central nervous system depressant (CNS depressant) activities of Propiverine.]
[P01BA02, hydroxychloroquine, The therapeutic efficacy of Pregabalin can be decreased when used in combination with Hydroxychloroquine.]
[N05AX07, prothipendyl, The therapeutic efficacy of Prothipendyl can be increased when used in combination with Pregabalin.]
[B05AA07, hetastarch, Pregabalin may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.]
[N05BB01, hydroxyzine, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Hydroxyzine.]
[R02AX02, ibuprofen, The risk or severity of angioedema can be increased when Pregabalin is combined with Ibuprofen.]
[B05XA08, sodium acetate, Pregabalin may decrease the excretion rate of Sodium acetate which could result in a higher serum level.]
[L01AA06, ifosfamide, Pregabalin may decrease the excretion rate of Ifosfamide which could result in a higher serum level.]
[N01AH03, sufentanil, The therapeutic efficacy of Sufentanil can be increased when used in combination with Pregabalin.]
[N06AA02, imipramine, The therapeutic efficacy of Imipramine can be increased when used in combination with Pregabalin.]
[H01BA04, terlipressin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Terlipressin.]
[R01AD07, tixocortol, Pregabalin may decrease the excretion rate of Tixocortol which could result in a higher serum level.]
[M03BX02, tizanidine, The therapeutic efficacy of Tizanidine can be increased when used in combination with Pregabalin.]
[L01CE01, topotecan, Pregabalin may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[C03BA11, indapamide, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Indapamide.]
[S01BC01, indomethacin, The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Indomethacin.]
[A11HA07, inositol, Pregabalin may decrease the excretion rate of Inositol which could result in a higher serum level.]
[N06AX17, milnacipran, The therapeutic efficacy of Milnacipran can be increased when used in combination with Pregabalin.]
[A03AA30, piperidolate, Pregabalin may increase the central nervous system depressant (CNS depressant) activities of Piperidolate.]
[S01XA28, varenicline, Pregabalin may decrease the excretion rate of Varenicline which could result in a higher serum level.]
[N01BB08, articaine, The therapeutic efficacy of Articaine can be increased when used in combination with Pregabalin.]
[A10BH01, sitagliptin, The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Sitagliptin.]
[V08AB02, iohexol, The therapeutic efficacy of Pregabalin can be decreased when used in combination with Iohexol.]
[N05BA12, alprazolam, The therapeutic efficacy of Alprazolam can be increased when used in combination with Pregabalin.]
[N05CH02, ramelteon, The therapeutic efficacy of Ramelteon can be increased when used in combination with Pregabalin.]
[R06AE01, buclizine, Pregabalin may increase the central nervous system depressant (CNS depressant) activities of Buclizine.]
[A10BH02, vildagliptin, The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Vildagliptin.]
[L01XX35, anagrelide, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Anagrelide.]
[C07AA01, alprenolol, The therapeutic efficacy of Alprenolol can be increased when used in combination with Pregabalin.]
[C03BA02, quinethazone, Quinethazone may increase the excretion rate of Pregabalin which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB01, ipecac, Pregabalin may decrease the excretion rate of Ipecac which could result in a higher serum level.]
[N06AA13, iprindole, The therapeutic efficacy of Iprindole can be increased when used in combination with Pregabalin.]
[N06AF05, iproniazid, The therapeutic efficacy of Iproniazid can be increased when used in combination with Pregabalin.]
[N05AA07, chlorproethazine, The therapeutic efficacy of Chlorproethazine can be increased when used in combination with Pregabalin.]
[N06AF01, isocarboxazid, The therapeutic efficacy of Isocarboxazid can be increased when used in combination with Pregabalin.]
[C09AA16, imidapril, The risk or severity of angioedema can be increased when Pregabalin is combined with Imidapril.]
[N01AB06, isoflurane, The therapeutic efficacy of Isoflurane can be increased when used in combination with Pregabalin.]
[N04BX02, entacapone, The therapeutic efficacy of Entacapone can be increased when used in combination with Pregabalin.]
[J04AC01, isoniazid, The therapeutic efficacy of Pregabalin can be decreased when used in combination with Isoniazid.]
[J05AX05, inosine pranobex, Pregabalin may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.]
[A10BJ01, exenatide, The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Exenatide.]
[C01DA14, isosorbide mononitrate, Pregabalin may increase the vasodilatory activities of Isosorbide mononitrate.]
[D10BA01, isotretinoin, Pregabalin may decrease the excretion rate of Isotretinoin which could result in a higher serum level.]
[N06AX18, reboxetine, The therapeutic efficacy of Reboxetine can be increased when used in combination with Pregabalin.]
[S01AA24, kanamycin, Pregabalin may decrease the excretion rate of Kanamycin which could result in a higher serum level.]
[N01AX03, ketamine, The therapeutic efficacy of Ketamine can be increased when used in combination with Pregabalin.]
[C02KD01, ketanserin, The therapeutic efficacy of Ketanserin can be increased when used in combination with Pregabalin.]
[B01AC22, prasugrel, Pregabalin may decrease the excretion rate of Prasugrel which could result in a higher serum level.]
[J02AB02, ketoconazole, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Ketoconazole.]
[N05AH03, olanzapine, The therapeutic efficacy of Olanzapine can be increased when used in combination with Pregabalin.]
[M02AA10, ketoprofen, Ketoprofen may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[R06AX25, mizolastine, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Mizolastine.]
[N04BC09, rotigotine, The therapeutic efficacy of Rotigotine can be increased when used in combination with Pregabalin.]
[A16AX01, thioctic acid, The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Pregabalin.]
[J01MB02, nalidixic acid, The therapeutic efficacy of Pregabalin can be decreased when used in combination with Nalidixic acid.]
[M01AE11, tiaprofenic acid, Tiaprofenic acid may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[D11AX02, gamma-linolenic acid, The therapeutic efficacy of Pregabalin can be decreased when used in combination with Gamolenic acid.]
[C07AG01, labetalol, Pregabalin may increase the bradycardic activities of Labetalol.]
[N04BB01, amantadine, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Amantadine.]
[A06AX03, lubiprostone, Pregabalin may decrease the excretion rate of Lubiprostone which could result in a higher serum level.]
[N03AX18, lacosamide, The therapeutic efficacy of Lacosamide can be increased when used in combination with Pregabalin.]
[C03CC01, ethacrynic acid, Etacrynic acid may increase the excretion rate of Pregabalin which could result in a lower serum level and potentially a reduction in efficacy.]
[G03AD01, levonorgestrel, The metabolism of Levonorgestrel can be increased when combined with Pregabalin.]
[N04BA01, levodopa, The therapeutic efficacy of Levodopa can be increased when used in combination with Pregabalin.]
[S02DA01, lidocaine, The therapeutic efficacy of Lidocaine can be increased when used in combination with Pregabalin.]
[C08EX01, lidoflazine, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Lidoflazine.]
[S01AA21, amikacin, Pregabalin may decrease the excretion rate of Amikacin which could result in a higher serum level.]
[C03DB01, amiloride, Amiloride may increase the excretion rate of Pregabalin which could result in a lower serum level and potentially a reduction in efficacy.]
[N02CA07, lisuride, The therapeutic efficacy of Lisuride can be increased when used in combination with Pregabalin.]
[N06AA07, lofepramine, The therapeutic efficacy of Lofepramine can be increased when used in combination with Pregabalin.]
[A07DA03, loperamide, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Loperamide.]
[N05BA06, lorazepam, The risk or severity of adverse effects can be increased when Pregabalin is combined with Lorazepam.]
[N05AH01, loxapine, The therapeutic efficacy of Loxapine can be increased when used in combination with Pregabalin.]
[G03DC03, lynestrenol, The metabolism of Lynestrenol can be increased when combined with Pregabalin.]
[L01EG01, temsirolimus, The risk or severity of angioedema can be increased when Pregabalin is combined with Temsirolimus.]
[B05XA11, magnesium chloride, Pregabalin may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.]
[G04BX01, magnesium hydroxide, Pregabalin may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.]
[V04CC02, magnesium sulfate, The therapeutic efficacy of Pregabalin can be increased when used in combination with Magnesium sulfate.]
[L01BA05, pralatrexate, Pregabalin may decrease the excretion rate of Pralatrexate which could result in a higher serum level.]
[L01EA03, nilotinib, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Nilotinib.]
[V04CX04, mannitol, Mannitol may increase the excretion rate of Pregabalin which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA21, maprotiline, The therapeutic efficacy of Maprotiline can be increased when used in combination with Pregabalin.]
[A08AA05, mazindol, The therapeutic efficacy of Mazindol can be increased when used in combination with Pregabalin.]
[C02BB01, mecamylamine, Pregabalin may decrease the excretion rate of Mecamylamine which could result in a higher serum level.]
[R06AE05, meclizine, The therapeutic efficacy of Meclizine can be increased when used in combination with Pregabalin.]
[M02AA18, meclofenamic acid, Meclofenamic acid may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[N05BA03, medazepam, The therapeutic efficacy of Medazepam can be increased when used in combination with Pregabalin.]
[P01BC02, mefloquine, The therapeutic efficacy of Pregabalin can be decreased when used in combination with Mefloquine.]
[C03BA05, mefruside, Mefruside may increase the excretion rate of Pregabalin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CH01, melatonin, The therapeutic efficacy of Melatonin can be increased when used in combination with Pregabalin.]
[N06DX01, memantine, Pregabalin may decrease the excretion rate of Memantine which could result in a higher serum level.]
[N02AB02, meperidine, The therapeutic efficacy of Meperidine can be increased when used in combination with Pregabalin.]
[N03AB04, mephenytoin, The therapeutic efficacy of Mephenytoin can be increased when used in combination with Pregabalin.]
[N03AA01, mephobarbital, The therapeutic efficacy of Methylphenobarbital can be increased when used in combination with Pregabalin.]
[N01BB03, mepivacaine, The therapeutic efficacy of Mepivacaine can be increased when used in combination with Pregabalin.]
[N05BC01, meprobamate, The therapeutic efficacy of Meprobamate can be increased when used in combination with Pregabalin.]
[N02AX05, meptazinol, The therapeutic efficacy of Meptazinol can be increased when used in combination with Pregabalin.]
[G04BX16, tiopronin, Pregabalin may decrease the excretion rate of Tiopronin which could result in a higher serum level.]
[C03BC01, mersalyl, Mersalyl may increase the excretion rate of Pregabalin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AC03, mesoridazine, The therapeutic efficacy of Mesoridazine can be increased when used in combination with Pregabalin.]
[N05AX13, paliperidone, The therapeutic efficacy of Paliperidone can be increased when used in combination with Pregabalin.]
[A10BA02, metformin, The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Metformin.]
[A04AA04, dolasetron, The therapeutic efficacy of Dolasetron can be increased when used in combination with Pregabalin.]
[H01CB03, lanreotide, The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Lanreotide.]
[N07BC02, methadone, The risk or severity of adverse effects can be increased when Methadone is combined with Pregabalin.]
[N06BA03, methamphetamine, The therapeutic efficacy of Metamfetamine can be increased when used in combination with Pregabalin.]
[A03AB07, methantheline, Pregabalin may increase the central nervous system depressant (CNS depressant) activities of Methantheline.]
[R06AC05, methapyrilene, The therapeutic efficacy of Methapyrilene can be increased when used in combination with Pregabalin.]
[N05CM01, methaqualone, The therapeutic efficacy of Methaqualone can be increased when used in combination with Pregabalin.]
[J05AF05, lamivudine, Pregabalin may decrease the excretion rate of Lamivudine which could result in a higher serum level.]
[N03AA30, metharbital, The therapeutic efficacy of Metharbital can be increased when used in combination with Pregabalin.]
[S01EC05, methazolamide, Methazolamide may increase the excretion rate of Pregabalin which could result in a lower serum level and potentially a reduction in efficacy.]
[G02CB05, metergoline, The therapeutic efficacy of Metergoline can be increased when used in combination with Pregabalin.]
[H03BB02, methimazole, Pregabalin may decrease the excretion rate of Methimazole which could result in a higher serum level.]
[L01BA04, pemetrexed, Pregabalin may decrease the excretion rate of Pemetrexed which could result in a higher serum level.]
[M03BA03, methocarbamol, The therapeutic efficacy of Methocarbamol can be increased when used in combination with Pregabalin.]
[N05CA15, methohexital, The therapeutic efficacy of Methohexital can be increased when used in combination with Pregabalin.]
[A11HA02, pyridoxine, Pyridoxine may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[N02BG08, ziconotide, The therapeutic efficacy of Ziconotide can be increased when used in combination with Pregabalin.]
[L04AX03, methotrexate, Methotrexate may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[N05AA02, methotrimeprazine, The therapeutic efficacy of Methotrimeprazine can be increased when used in combination with Pregabalin.]
[D05BA02, methoxsalen, Pregabalin may decrease the excretion rate of Methoxsalen which could result in a higher serum level.]
[N02BG09, methoxyflurane, The therapeutic efficacy of Methoxyflurane can be increased when used in combination with Pregabalin.]
[C03AA08, methyclothiazide, Methyclothiazide may increase the excretion rate of Pregabalin which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AB01, methyldopa, Pregabalin may increase the bradycardic activities of Methyldopa.]
[V04CG05, methylene blue, The therapeutic efficacy of Methylene blue can be increased when used in combination with Pregabalin.]
[R03DA05, aminophylline, Pregabalin may increase the excretion rate of Aminophylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N06BA04, methylphenidate, The therapeutic efficacy of Pregabalin can be decreased when used in combination with Methylphenidate.]
[N03AF03, rufinamide, The therapeutic efficacy of Rufinamide can be increased when used in combination with Pregabalin.]
[G03EK01, methyltestosterone, Pregabalin may decrease the excretion rate of Methyltestosterone which could result in a higher serum level.]
[N05CE02, methyprylon, The therapeutic efficacy of Methyprylon can be increased when used in combination with Pregabalin.]
[N02CA04, methysergide, The therapeutic efficacy of Methysergide can be increased when used in combination with Pregabalin.]
[A03FA01, metoclopramide, The risk or severity of sedation can be increased when Metoclopramide is combined with Pregabalin.]
[C03BA08, metolazone, Metolazone may increase the excretion rate of Pregabalin which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB02, metoprolol, Pregabalin may increase the bradycardic activities of Metoprolol.]
[P01AB01, metronidazole, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Metronidazole.]
[V04CD01, metyrapone, Pregabalin may decrease the excretion rate of Metyrapone which could result in a higher serum level.]
[N06AX03, mianserin, The therapeutic efficacy of Pregabalin can be decreased when used in combination with Mianserin.]
[N02BB03, aminopyrine, Aminophenazone may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[N05CD08, midazolam, The therapeutic efficacy of Midazolam can be increased when used in combination with Pregabalin.]
[C01CA17, midodrine, Midodrine may increase the bradycardic activities of Pregabalin.]
[G03XB01, mifepristone, The metabolism of Mifepristone can be increased when combined with Pregabalin.]
[J05AH01, zanamivir, Pregabalin may decrease the excretion rate of Zanamivir which could result in a higher serum level.]
[C09CA03, valsartan, The risk or severity of angioedema can be increased when Valsartan is combined with Pregabalin.]
[J01AA08, minocycline, Minocycline may increase the central nervous system depressant (CNS depressant) activities of Pregabalin.]
[N05AE02, molindone, The therapeutic efficacy of Molindone can be increased when used in combination with Pregabalin.]
[L03AC01, aldesleukin, Aldesleukin may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[C01BD01, amiodarone, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Amiodarone.]
[N06AA09, amitriptyline, The therapeutic efficacy of Amitriptyline can be increased when used in combination with Pregabalin.]
[N02AA01, morphine, The therapeutic efficacy of Morphine can be increased when used in combination with Pregabalin.]
[A04AA05, palonosetron, The therapeutic efficacy of Palonosetron can be increased when used in combination with Pregabalin.]
[J01DD06, moxalactam, Latamoxef may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[L04AB05, certolizumab pegol, Pregabalin may decrease the excretion rate of Certolizumab pegol which could result in a higher serum level.]
[G04BA01, ammonium chloride, Pregabalin may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.]
[L01EX03, pazopanib, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Pazopanib.]
[L04AA06, mycophenolic acid, Pregabalin may decrease the excretion rate of Mycophenolic acid which could result in a higher serum level.]
[M03AC03, vecuronium, The therapeutic efficacy of Vecuronium can be increased when used in combination with Pregabalin.]
[N05CA02, amobarbital, The therapeutic efficacy of Amobarbital can be increased when used in combination with Pregabalin.]
[P01BA06, amodiaquine, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Amodiaquine.]
[R03BB01, ipratropium bromide, Pregabalin may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AA17, amoxapine, The therapeutic efficacy of Amoxapine can be increased when used in combination with Pregabalin.]
[N03AB05, fosphenytoin, The therapeutic efficacy of Fosphenytoin can be increased when used in combination with Pregabalin.]
[C07AA12, nadolol, Pregabalin may increase the bradycardic activities of Nadolol.]
[J01CA04, amoxicillin, Pregabalin may decrease the excretion rate of Amoxicillin which could result in a higher serum level.]
[N04BC04, ropinirole, Pregabalin may increase the sedative activities of Ropinirole.]
[C04AX21, nafronyl, The therapeutic efficacy of Naftidrofuryl can be increased when used in combination with Pregabalin.]
[N02AF02, nalbuphine, The therapeutic efficacy of Nalbuphine can be increased when used in combination with Pregabalin.]
[V03AB15, naloxone, Pregabalin may decrease the excretion rate of Naloxone which could result in a higher serum level.]
[N07BB04, naltrexone, The risk or severity of respiratory depression can be increased when Naltrexone is combined with Pregabalin.]
[S01GA01, naphazoline, The risk or severity of CNS depression can be increased when Naphazoline is combined with Pregabalin.]
[N06BA01, amphetamine, The therapeutic efficacy of Pregabalin can be decreased when used in combination with Amphetamine.]
[M02AA12, naproxen, Naproxen may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[A10BG01, troglitazone, The risk or severity of weight gain and edema formation can be increased when Pregabalin is combined with Troglitazone.]
[N06AX21, duloxetine, The therapeutic efficacy of Duloxetine can be increased when used in combination with Pregabalin.]
[N04BX01, tolcapone, The therapeutic efficacy of Tolcapone can be increased when used in combination with Pregabalin.]
[S03AA01, neomycin, Pregabalin may decrease the excretion rate of Neomycin which could result in a higher serum level.]
[N01AH06, remifentanil, The therapeutic efficacy of Remifentanil can be increased when used in combination with Pregabalin.]
[A10BX02, repaglinide, The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Repaglinide.]
[C01CX08, levosimendan, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Levosimendan.]
[B01AC17, tirofiban, Pregabalin may decrease the excretion rate of Tirofiban which could result in a higher serum level.]
[N05AX14, iloperidone, The therapeutic efficacy of Iloperidone can be increased when used in combination with Pregabalin.]
[J02AA01, amphotericin B, The therapeutic efficacy of Pregabalin can be decreased when used in combination with Amphotericin B.]
[S01AA19, ampicillin, Pregabalin may decrease the excretion rate of Ampicillin which could result in a higher serum level.]
[L03AX16, plerixafor, Pregabalin may decrease the excretion rate of Plerixafor which could result in a higher serum level.]
[S01AA23, netilmicin, Pregabalin may decrease the excretion rate of Netilmicin which could result in a higher serum level.]
[N06AX23, desvenlafaxine, The therapeutic efficacy of Desvenlafaxine can be increased when used in combination with Pregabalin.]
[C09CA07, telmisartan, The risk or severity of angioedema can be increased when Pregabalin is combined with Telmisartan.]
[J05AB11, valacyclovir, Valaciclovir may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[C01CE01, inamrinone, Pregabalin may decrease the excretion rate of Amrinone which could result in a higher serum level.]
[N06AF02, nialamide, The therapeutic efficacy of Nialamide can be increased when used in combination with Pregabalin.]
[C08CA04, nicardipine, Pregabalin may increase the central nervous system depressant (CNS depressant) activities of Nicardipine.]
[C08CA05, nifedipine, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Nifedipine.]
[M02AA17, niflumic acid, Niflumic acid may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[C08CA06, nimodipine, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Nimodipine.]
[C08CA07, nisoldipine, Pregabalin may increase the bradycardic activities of Nisoldipine.]
[N05CD02, nitrazepam, The therapeutic efficacy of Nitrazepam can be increased when used in combination with Pregabalin.]
[C08CA08, nitrendipine, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Nitrendipine.]
[R07AX01, nitric oxide, Pregabalin may decrease the excretion rate of Nitric Oxide which could result in a higher serum level.]
[J01XE01, nitrofurantoin, Pregabalin may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.]
[N05CF03, zaleplon, The therapeutic efficacy of Zaleplon can be increased when used in combination with Pregabalin.]
[N04BC05, pramipexole, Pregabalin may increase the sedative activities of Pramipexole.]
[C02DD01, nitroprusside, Pregabalin may decrease the excretion rate of Nitroprusside which could result in a higher serum level.]
[N01AX13, nitrous oxide, The therapeutic efficacy of Nitrous oxide can be increased when used in combination with Pregabalin.]
[N06AX04, nomifensine, The therapeutic efficacy of Nomifensine can be increased when used in combination with Pregabalin.]
[G03DC02, norethindrone, The metabolism of Norethisterone can be increased when combined with Pregabalin.]
[S01AE02, norfloxacin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Norfloxacin.]
[G03AC07, norgestrienone, The metabolism of Norgestrienone can be increased when combined with Pregabalin.]
[N06AA10, nortriptyline, The therapeutic efficacy of Nortriptyline can be increased when used in combination with Pregabalin.]
[G02CA02, nylidrin, Pregabalin may increase the bradycardic activities of Nylidrin.]
[H01CB02, octreotide, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Pregabalin.]
[S02AA16, ofloxacin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Ofloxacin.]
[N06AA05, opipramol, The therapeutic efficacy of Opipramol can be increased when used in combination with Pregabalin.]
[N02AA02, opium, The therapeutic efficacy of Opium can be increased when used in combination with Pregabalin.]
[B01AD07, reteplase, The risk or severity of angioedema can be increased when Reteplase is combined with Pregabalin.]
[G04CA02, tamsulosin, Pregabalin may decrease the excretion rate of Tamsulosin which could result in a higher serum level.]
[J01CF04, oxacillin, Pregabalin may decrease the excretion rate of Oxacillin which could result in a higher serum level.]
[N05BA04, oxazepam, The therapeutic efficacy of Oxazepam can be increased when used in combination with Pregabalin.]
[J01MB05, oxolinic acid, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Oxolinic acid.]
[C07AA02, oxprenolol, The therapeutic efficacy of Oxprenolol can be increased when used in combination with Pregabalin.]
[N02AA05, oxycodone, The risk or severity of adverse effects can be increased when Pregabalin is combined with Oxycodone.]
[N02AA11, oxymorphone, The therapeutic efficacy of Oxymorphone can be increased when used in combination with Pregabalin.]
[N05AE01, oxypertine, The therapeutic efficacy of Oxypertine can be increased when used in combination with Pregabalin.]
[S01BC02, oxyphenbutazone, Oxyphenbutazone may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[A03AB03, oxyphenonium, Pregabalin may increase the central nervous system depressant (CNS depressant) activities of Oxyphenonium.]
[H01BB02, oxytocin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Pregabalin.]
[N05AH05, asenapine, The therapeutic efficacy of Asenapine can be increased when used in combination with Pregabalin.]
[N02AX06, tapentadol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Pregabalin.]
[M03AC01, pancuronium, The therapeutic efficacy of Pancuronium can be increased when used in combination with Pregabalin.]
[J04AB30, capreomycin, Pregabalin may decrease the excretion rate of Capreomycin which could result in a higher serum level.]
[G03DB06, chlormadinone, The metabolism of Chlormadinone can be increased when combined with Pregabalin.]
[G04BE02, papaverine, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Papaverine.]
[N05CC05, paraldehyde, The therapeutic efficacy of Paraldehyde can be increased when used in combination with Pregabalin.]
[C02KC01, pargyline, The therapeutic efficacy of Pargyline can be increased when used in combination with Pregabalin.]
[A07AA06, paromomycin, Paromomycin may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[J01MA03, pefloxacin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Pefloxacin.]
[G04BD11, fesoterodine, Pregabalin may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.]
[C07AA23, penbutolol, The therapeutic efficacy of Penbutolol can be increased when used in combination with Pregabalin.]
[N05AG03, penfluridol, The therapeutic efficacy of Penfluridol can be increased when used in combination with Pregabalin.]
[J01CE09, penicillin G procaine, Pregabalin may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.]
[N02AD01, pentazocine, The therapeutic efficacy of Pentazocine can be increased when used in combination with Pregabalin.]
[N05CA01, pentobarbital, The therapeutic efficacy of Pentobarbital can be increased when used in combination with Pregabalin.]
[L01XX08, pentostatin, Pregabalin may decrease the excretion rate of Pentostatin which could result in a higher serum level.]
[C04AD03, pentoxifylline, Pregabalin may increase the excretion rate of Pentoxifylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AB10, perazine, The therapeutic efficacy of Perazine can be increased when used in combination with Pregabalin.]
[N04BC02, pergolide, The therapeutic efficacy of Pergolide can be increased when used in combination with Pregabalin.]
[C08EX02, perhexiline, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Perhexiline.]
[N05AB03, perphenazine, The therapeutic efficacy of Perphenazine can be increased when used in combination with Pregabalin.]
[N02AD02, phenazocine, The therapeutic efficacy of Phenazocine can be increased when used in combination with Pregabalin.]
[G04BX06, phenazopyridine, Phenazopyridine may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[N06AF03, phenelzine, The therapeutic efficacy of Phenelzine can be increased when used in combination with Pregabalin.]
[A10BA01, phenformin, The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Phenformin.]
[R06AB05, pheniramine, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Pheniramine.]
[N01AH04, phenoperidine, The therapeutic efficacy of Phenoperidine can be increased when used in combination with Pregabalin.]
[V03AB36, phentolamine, Pregabalin may decrease the excretion rate of Phentolamine which could result in a higher serum level.]
[M02AA01, phenylbutazone, Phenylbutazone may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[R01BA01, phenylpropanolamine, The therapeutic efficacy of Pregabalin can be decreased when used in combination with Phenylpropanolamine.]
[S01AE05, levofloxacin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Levofloxacin.]
[B02BA01, vitamin K1, Pregabalin may decrease the excretion rate of Phylloquinone which could result in a higher serum level.]
[J05AB12, cidofovir, Cidofovir may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[C08CX01, mibefradil, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Mibefradil.]
[N05AG02, pimozide, The therapeutic efficacy of Pimozide can be increased when used in combination with Pregabalin.]
[C07AA03, pindolol, The therapeutic efficacy of Pindolol can be increased when used in combination with Pregabalin.]
[J01CA12, piperacillin, Pregabalin may decrease the excretion rate of Piperacillin which could result in a higher serum level.]
[J05AE01, saquinavir, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Saquinavir.]
[N05AC04, pipothiazine, The therapeutic efficacy of Pipotiazine can be increased when used in combination with Pregabalin.]
[N06BX03, piracetam, Pregabalin may decrease the excretion rate of Piracetam which could result in a higher serum level.]
[C09CA02, eprosartan, The risk or severity of angioedema can be increased when Pregabalin is combined with Eprosartan.]
[A02BX03, pirenzepine, Pregabalin may increase the central nervous system depressant (CNS depressant) activities of Pirenzepine.]
[N02AC03, pirinitramide, The therapeutic efficacy of Piritramide can be increased when used in combination with Pregabalin.]
[S01BC06, piroxicam, Piroxicam may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[J01DD16, cefditoren, Cefditoren may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[J01MA11, grepafloxacin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Grepafloxacin.]
[N02CX01, pizotyline, The therapeutic efficacy of Pizotifen can be increased when used in combination with Pregabalin.]
[N05CA22, proxibarbal, The therapeutic efficacy of Proxibarbal can be increased when used in combination with Pregabalin.]
[S01XA13, alteplase, The risk or severity of angioedema can be increased when Alteplase is combined with Pregabalin.]
[A10BG02, rosiglitazone, The risk or severity of weight gain and edema formation can be increased when Pregabalin is combined with Rosiglitazone.]
[A03AE01, alosetron, The therapeutic efficacy of Alosetron can be increased when used in combination with Pregabalin.]
[C03AA05, polythiazide, Polythiazide may increase the excretion rate of Pregabalin which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AE03, ritonavir, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Ritonavir.]
[A10BH03, saxagliptin, The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Saxagliptin.]
[B05XA01, potassium chloride, Pregabalin may decrease the excretion rate of Potassium chloride which could result in a higher serum level.]
[A10AD04, insulin lispro, The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Insulin lispro.]
[C07AB01, practolol, Pregabalin may increase the bradycardic activities of Practolol.]
[C01BA08, prajmaline, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Prajmaline.]
[N05BA11, prazepam, The therapeutic efficacy of Prazepam can be increased when used in combination with Pregabalin.]
[H02AB07, prednisone, Pregabalin may decrease the excretion rate of Prednisone which could result in a higher serum level.]
[R06AX05, antazoline, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Antazoline.]
[C01DX02, prenylamine, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Prenylamine.]
[N01BB04, prilocaine, The therapeutic efficacy of Prilocaine can be increased when used in combination with Pregabalin.]
[P01BA03, primaquine, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Primaquine.]
[N03AA03, primidone, The therapeutic efficacy of Primidone can be increased when used in combination with Pregabalin.]
[M04AB01, probenecid, Pregabalin may decrease the excretion rate of Probenecid which could result in a higher serum level.]
[C10AX02, probucol, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Probucol.]
[C01BA02, procainamide, Pregabalin may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[S01HA05, procaine, The therapeutic efficacy of Procaine can be increased when used in combination with Pregabalin.]
[L01XB01, procarbazine, The therapeutic efficacy of Procarbazine can be increased when used in combination with Pregabalin.]
[C10AB05, fenofibrate, Pregabalin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.]
[N05AB04, prochlorperazine, The therapeutic efficacy of Prochlorperazine can be increased when used in combination with Pregabalin.]
[N04AA04, procyclidine, Pregabalin may increase the central nervous system depressant (CNS depressant) activities of Procyclidine.]
[G03DA04, progesterone, The metabolism of Progesterone can be increased when combined with Pregabalin.]
[N05AA03, promazine, The therapeutic efficacy of Promazine can be increased when used in combination with Pregabalin.]
[R06AD02, promethazine, The therapeutic efficacy of Promethazine can be increased when used in combination with Pregabalin.]
[C01BC03, propafenone, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Propafenone.]
[N01AX04, propanidid, The therapeutic efficacy of Propanidid can be increased when used in combination with Pregabalin.]
[A03AB05, propantheline, Pregabalin may increase the central nervous system depressant (CNS depressant) activities of Propantheline.]
[N05AC01, periciazine, The therapeutic efficacy of Periciazine can be increased when used in combination with Pregabalin.]
[N05CM06, propiomazine, The therapeutic efficacy of Propiomazine can be increased when used in combination with Pregabalin.]
[L01XH02, romidepsin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Romidepsin.]
[N01AX10, propofol, The therapeutic efficacy of Propofol can be increased when used in combination with Pregabalin.]
[N02AC04, propoxyphene, The therapeutic efficacy of Dextropropoxyphene can be increased when used in combination with Pregabalin.]
[C07AA05, propranolol, Pregabalin may increase the bradycardic activities of Propranolol.]
[N02CC04, rizatriptan, The therapeutic efficacy of Rizatriptan can be increased when used in combination with Pregabalin.]
[B01AC09, epoprostenol, Pregabalin may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[N06AA11, protriptyline, The therapeutic efficacy of Protriptyline can be increased when used in combination with Pregabalin.]
[N05AX12, aripiprazole, The therapeutic efficacy of Aripiprazole can be increased when used in combination with Pregabalin.]
[N07XX07, dalfampridine, Pregabalin may decrease the excretion rate of Dalfampridine which could result in a higher serum level.]
[A03AB15, diphemanil, Pregabalin may increase the central nervous system depressant (CNS depressant) activities of Diphemanil.]
[A03AB09, isopropamide, Pregabalin may increase the central nervous system depressant (CNS depressant) activities of Isopropamide.]
[S01FA03, methscopolamine, Pregabalin may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.]
[N05CA07, talbutal, The therapeutic efficacy of Talbutal can be increased when used in combination with Pregabalin.]
[N05CA09, vinbarbital, The therapeutic efficacy of Vinbarbital can be increased when used in combination with Pregabalin.]
[N05BB02, captodiamine, The therapeutic efficacy of Captodiame can be increased when used in combination with Pregabalin.]
[M03BA04, styramate, The therapeutic efficacy of Styramate can be increased when used in combination with Pregabalin.]
[P02CC01, pyrantel, The therapeutic efficacy of Pyrantel can be increased when used in combination with Pregabalin.]
[J04AK01, pyrazinamide, Pregabalin may decrease the excretion rate of Pyrazinamide which could result in a higher serum level.]
[R06AC01, pyrilamine, The therapeutic efficacy of Mepyramine can be increased when used in combination with Pregabalin.]
[C01BA01, quinidine, Pregabalin may decrease the excretion rate of Quinidine which could result in a higher serum level.]
[P01BC01, quinine, The therapeutic efficacy of Quinine can be increased when used in combination with Pregabalin.]
[A02BA02, ranitidine, Pregabalin may decrease the excretion rate of Ranitidine which could result in a higher serum level.]
[C02AA01, rescinnamine, The risk or severity of angioedema can be increased when Pregabalin is combined with Rescinnamine.]
[C02AA02, reserpine, The therapeutic efficacy of Reserpine can be increased when used in combination with Pregabalin.]
[J05AP01, ribavirin, Pregabalin may decrease the excretion rate of Ribavirin which could result in a higher serum level.]
[N06AX01, 5-hydroxytryptophan, The therapeutic efficacy of Oxitriptan can be increased when used in combination with Pregabalin.]
[J01FA06, roxithromycin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Roxithromycin.]
[N02BA05, salicylamide, Salicylamide may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[A07EC01, sulfasalazine, Sulfasalazine may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[S01BC08, salicylic acid, Salicylic acid may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[S01FA02, scopolamine, The therapeutic efficacy of Scopolamine can be increased when used in combination with Pregabalin.]
[N05CA06, secobarbital, The therapeutic efficacy of Secobarbital can be increased when used in combination with Pregabalin.]
[N04BD01, selegiline, The therapeutic efficacy of Selegiline can be increased when used in combination with Pregabalin.]
[J01GB08, sisomicin, Pregabalin may decrease the excretion rate of Sisomicin which could result in a higher serum level.]
[A12CD01, sodium fluoride, Pregabalin may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.]
[V04CC01, sorbitol, Pregabalin may decrease the excretion rate of Sorbitol which could result in a higher serum level.]
[C07AA07, sotalol, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Sotalol.]
[C03DA01, spironolactone, Spironolactone may increase the excretion rate of Pregabalin which could result in a lower serum level and potentially a reduction in efficacy.]
[V09AB03, ioflupane I-123, Pregabalin may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.]
[V09AA01, technetium Tc 99m exametazime, Pregabalin may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.]
[V09AX06, florbetaben f-18, Pregabalin may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.]
[D10AX03, azelaic acid, Pregabalin may decrease the excretion rate of Azelaic acid which could result in a higher serum level.]
